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I 
FOREWORD 
I 
The Apollo-Soyuz Test Project (ASTP) was both an end and a beginning. 
It was the final flight of the highly successful Apollo program. It was the last 
time that three U.S. astronauts, tightly packed into a command module, would 
launch from an expendable booster, elbow their way through space, and then 
return gracefully to a salty splashdown. 
But it was the first time that an international purpose to  manned flight was 
demonstrated. Joint docking and the sharing of quarters, experiments, and pro- 
visions have all symbolized the feasibility and the will of cooperative space explora- 
tion. 
As we summarize the Life Sciences findings of this mission, we look forward 
to  the future. We are confident that international manned missions will continue 
in ever increasing frequency and duration. We are also confident that we will be 
able t o  support these missions and to insure the health and well-being of all space 
travelers. 
January 1977 
DAVID L. WINTER, M.D. 
NASA Director for Life Sciences 
V 
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PREFACE 
The Apollo-Soyuz mission was the first space flight t o  be conducted jointly by the two 
leading nations in space exploration, the United States and the U.S.S.R. The primary purpose 
of this mission was to test systems for rendezvous and docking of manned spacecraft as might 
occur in standard international space rescue missions and,consequently, t o  demonstrate the 
ability to effect crew transfer between spacecraft. The secondary purpose of the mission was 
to conduct a program of science experiments and technology applications. Except for minor 
modification, the Apollo and Soyuz spacecraft were identical with those flown on previous 
missions. A specially constructed docking module was used in flight for crew transfer and 
also served as the structural base for the docking mechanism that interfaced with a similar 
mechanism on the Soyuz spacecraft. 
This mission, officially known as the Apollo-Soyuz Test Project (ASTP), brought the 
Apollo Program to  a successful conclusion. While marking the end of an era, it also heralded 
the beginning of increased international cooperation in the space age. The rescue of man in 
space as a feasible operation on an international basis, should the need arise, was demonstrated. 
research studies that were performed on the astronauts. Because of the compromised post- 
flight crew health status, not all postflight research procedures could be accomplished. This 
compromise was the result of the anomalous entrance of toxic gas into the spacecraft cabin 
during the Earth landing sequence. Despite the exposure, the medical data collected are of 
sufficient interest to warrant inclusion in this official ASTP Medical Report. 
Microbial Exchange and Zone-Forming Fungi. The medical microbiological analysis of the 
U.S. crewmembers is reported in chapter 13 of this report. The Microbial Exchange experi- 
ment, which includes the data from the U.S.S.R. cosmonauts, and the other six (U.S.) 
science experiments - Quantitative Observation of Light Flash Sensation, Biostack 111, 
Zone-Forming Fungi, Cellular Immune Response, The Effects of Space Flight on Polymor- 
phonuclear Leukocyte Response, and Killifish Hatching and Orientation - are reported 
elsewhere (see Bibliography). 
A most impelling portion of this report is concerned with the entry phase of the mission, 
when the crew was exposed to toxic nitrogen tetroxide gas, and with their subsequent clinical 
course and uneventful convalescence. The problem was managed expeditiously and expertly 
by the crew’s flight surgeons and team of medical consultants, both onboard ship and at the 
Tripler Army Medical Center, Honolulu, Hawaii. 
The Apollo era has ended with the ASTP flight. Thus, a remarkable series of space mis- 
sions - prelunar and lunar Apollo, Skylab, and ASTP - has been concluded. These ventures 
are now history, and the Space Shuttle era will further the understanding of man in the space 
environment he has come to  know and respect. 
This report details the results of the clinical aspects as well as the preflight and postflight 
Only two joint US-U.S.S.R. life scienceskxperiments were included in this mission: 
LAWRENCE F. DIETLEIN 
NASA Lyndon B, Johnson Space Center 
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SECTION I 
BACKGROUND 

1. U.S. AND U.S.S.R. MEDICAL NEGOTIATIONS AND AGREEMENTS 
Arnauld E. Nicogossiana and Willard R. Hawkinsa 
I 
This discussion of medical negotiations and agreements between representatives of the 
United States and the U.S.S.R. is presented chronologically. 
1972 
Joint U.S. and U.S.S.R. negotiations for the Apollo-Soyuz Test Project (ASTP) were 
conducted at regular intervals by the U.S. and U.S.S.R. specialists a t  the NASA Lyndon B. 
Johnson Space Center (JSC) in the United States and, under the auspices of the U.S.S.R. 
Academy of  Sciences, in the U.S.S.R. Preliminary discussions were held October 9 to 19, 
1972, in Moscow, U.S.S.R. During this meeting, medical specialists of Working Group I11 
discussed in-flight crew safety, crew transfers, and an in-flight medical support system. 
In addition, they exchanged several preliminary life sciences documents relating to  the 
proposed joint venture. 
I 
1973 
I The heavy schedules imposed by the Skylab orbital missions limited medical negotia- 
tions in 1973 to the two joint life sciences experiments, Microbial Exchange and Zone- 
Forming Fungi. 
1974and 1975 
After completion of the Skylab space flights in 1974, negotiations relating to the 
medical requirements were renewed, and a joint session was held a t  JSC from January 14 
t o  February 1, 1974. Appointed representatives of the two countries exchanged general 
information about the preflight, in-flight, and postflight medical evaluations; schedules; 
and a flight crew health stabilization program. The negotiations and the intent to follow 
up with appropriate documentation and preparation of  a U.S.-U.S.S.R. working group 
reference document for medical requirements are recorded in the official minutes of the 
meeting by Working Group I .  The next meeting, April 8 to  May 3, 1974, was held again 
at JSC. Before this meeting, both countries exchanged documents regarding their respec- 
tive medical requirements. At this meeting, discussion included flight crew health stabiliza- 
tion programs (21 days before flight for the United States and 10 days for the U.S.S.R.), 
in-flight bioinstrumentation, possible drug kit exchange, drug testing, schedules, and 
protocols for in-flight crew transfers. Since the internal life sciences ASTP medical re- 
quirements document was not completed, only preliminary plans for the preflight and 
postflight medical examination time lines were discussed at the time of this meeting. The 
preflight and postflight medical requirements for both countries were finalized during the 
aNASA Lyndon B. Johnson Space Center. 
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succeeding meeting, held in Moscow, between August 26 and September 13, 1974. The in- 
flight medical requirements were completed and added to the overall medical requirements 
documents during a meeting held January 30 to  February 13, 1975, at JSC. 
independently tailored by each country. Though the main objectives of both programs are 
identical (i.e., the study of man’s physiology in space and optimum in-flight crew health 
maintenance), the methods of accomplishing these objectives are dissimilar and generally 
reflect each country’s respective medical philosophies. At the start of the ASTP medical 
negotiations, experimental procedures for only two types of medical protocol (i.e., lower 
body negative pressure and blood biochemical evaluations) had been agreed to  under the 
auspices of the U.S.-U.S.S.R. Joint Working Group on Space Biology and Medicine. Thus, 
the major portion of the medical evaluations and the respective time lines had to  be dis- 
cussed and unified during the available time apportioned for the meetings of ASTP working 
groups. The small number of medical representatives participating at any time in the 
negotiations and the increased secretarial and translator support that was needed accounted 
for a delay in completion of the joint phase of the biomedical program. 
medical requirements document will be published separately at a later date. 
contact between medical personnel of the two countries had been established for the ASTP 
in-flight portion of the mission. It was decided that, in case of need, communications 
between medical staffs would be routed through the Joint Flight Directors Loop. Also, 
the final medical findings from this mission would be presented during a regular session of 
the joint U.S.-U.S.S.R. Working Group on Space Biology and Medicine. 
Before ASTP, life sciences programs to  be implemented in manned space flights were 
For historical purposes, the final English language version of the ASTP U.S.-U.S.S.R. 
Because each country was allowed to proceed with its respective program, no official 
4 
SECTION I1 
CREW HEALTH AND FLIGHT MONITORING 

2. GENERAL BIOMEDICAL EVALUATION 
Arnauld E. Nicogossian,a Eduard C. Burchard,a and Jerry R. Hordinsk ya 
Four areas of importance in health preventive maintenance became apparent from pre- 
1. The flight medicine support system and drug testing 
2. The work/rest cycle 
3. In-flight exercise and bioinstrumentation 
4. Food and nutrition. 
Comprehensive preflight physical examinations were conducted 30, 15, and 5 days 
vious Apollo and Skylab space missions. These four areas are: 
before launch. Additional abbreviated physical examinations were conducted daily start- 
ing 3 days before launch. The individual tolerance drug testing was done 3 months before 
the space flight, and no significant problems were encountered in either prime or  backup 
crewmen. 
tetroxide and subsequently hospitalized at the Tripler Army Medical Center, Honolulu, 
Hawaii. Consequently, most preplanned postflight medical activities not directly related 
to  crew health were canceled. 
which provided for in-flight diagnosis and treatment of a possible illness, was considered 
practical for a short, 9-day flight. Two cardiovascular drugs, quinidine sulfate and dipyrid- 
amole, were added to  the IMSS medication list in deference to  the past medical history of 
one crewmember. The short duration of the mission and inadequate medical training of the 
crew precluded the addition of such diagnostic equipment as a stethoscope or a blood pres- 
sure measuring system into the IMSS. The overall medical IMSS training, limited to  a 2- 
hour general discussion with the command module pilot, covered indications for usage of 
the available drugs. In addition to the IMSS, data from the operational bioinstrumentation 
system would also be used, as indicated, as a diagnostic aid to  assist in the recommendation 
for treatment. 
training, would consult with the crew surgeon and/or Mission Operations Control Room 
(MOCR) surgeon over the open loop of the air-to-ground communication system, should 
the need arise. The private medical communication loop would be reserved for use on the 
crew’s request only and with the flight director’s approval. 
It should be mentioned that in the very early phase of preflight preparations, each 
U.S.S.R. prime and backup crewman received a briefing regarding drugs contained in the 
U.S. medical kit. Further attempts to formally translate U.S. drugs and modes of utiliza- 
tion into written Russian were not successful. By the start of the mission, a list of the 
Soyuz drugs was available. It was translated into English by the efforts of U.S.S.R. med- 
ical personnel, and it included some indication of drug utilization, mode, and dosages. 
Although crude, this list served as a reference for the MOCR medical personnel. 
In the entry phase of the mission, the crew was exposed t o  the toxic fumes of nitrogen 
For mission completion, a modified Apollo in-flight medical support system (IMSS), 
It was agreed before the actual flight that the crewmembers, because of their limited 
aNASA Lyndon B. Johnson Space Center. 
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During the 21-day preflight crew health stabilization program, the crew was maintained 
on a nominal work/rest schedule. This schedule permitted the crewmembers t o  have a daily 
exercise period and at least 7 hours of good night rest. It also included scheduled work and 
some time for recreation each week. 
During the flight period, changes to the flight plan occasionally interrupted the periods 
of planned crew sleep. The estimate of sleep duration made by ground personnel was in 
general agreement with the subjective evaluation of the crew. The difference in the launch 
and zone times of both countries and the scheduled time lines for in-flight joint activities 
inevitably led t o  operational circadian shifts for both crews. The resulting in-flight circadian 
shifts for the U.S. crewmen are depicted in Figures 2-1 and 2-2, where F - 2 is 2 days before 
lift-off, F - 1 is 1 day before lift-off, and R + 0 is recovery day. The duration of sleep, sleep 
interruptions, and the magnitude of circadian shifts required for the successful completion 
of in-flight joint activities are shown in the figures. In summary, a total of three major sleep/ 
wake cycle shifts occurred during this short-duration mission; the most significant shift of 
approximately 4.5 hours occurred on mission day 2. 
MD-2 
MD-3 
t MD-4 MD-5 m 0 
I Houston 1 - 
I 
I MD-2 CO 
Cape Kennedy I 
+ 
Mission day (MD) 1 1 * 
MD-3 1 
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- - 
I MD-6 1 
I 
I MD-8 1 
-t 
MD-6 
MD-7 1 
MD-8 
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MD-7 
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- + 
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Figure 2-1. Apollo-Soyuz Test Project Sleep Time and Circadian Shift (U.S. Crew) 
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Figure 2-2. Apollo-Soyuz Test Project Circadian Shift (US. Crew) 
The sporadic increase in the command module ambient temperature (to as high as 
299.8 k (26.6' C) (80' F)) during the latter part of the mission did not significantly affect 
the overall in-flight work/rest cycle. 
Flight menus were designed to meet individual energy requirements under normal 
gravity conditions. The total daily caloric intake requirement was computed before the 
flight from lean body mass measurements. This topic is discussed in detail in Chapter 6. 
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3. CREW HEALTH 
Arnauld E. Nicogossian,a Charles K. LaPinta,a Eduard C. Burchard,a 
G. Wyckliffe Hoffler? and Peter J.  Batellonib 
SUMMARY OF CLINICAL FINDINGS 
Preflight Crew Health Status 
Medical examinations were performed on the three crewmembers at specific intervals 
during the 30-day preflight period. In anticipation of a long and busy launch day, each 
crewman attempted to  establish a more operationally desirable sleep/work cycle 2 days 
before lift-off (F - 2) and 1 day before lift-off (F - 1)  by going to  sleep at approximately 
03:OO G.m.t. (1 1:OO p.m. e.d.t.) and waking up at 13:OO G.m.t. (9:OO a.m. e.d.t.); no 
hypnotic medications were used during this period. On day F - 4, all crewmembers were 
on a low-residue diet. To further reduce the fecal content in his bowels, each crewman 
used a Travad enema and two Pericolace tablets on F - 1. During the preflight physical 
examinations, no  significant medical problems were detected in the prime and backup 
crewmembers. There were no changes in their health status, and their health remained 
good throughout the preflight phase of the mission. The Apollo commander (ACDR) was 
not subjected t o  studies involving radiation procedures because of a past history of expo- 
sure t o  high radiation levels. 
, 
j 
In-Flight Crew Health Status 
The physical status of the ACDR, the command module pilot (CMP), and the dock- 
ing module pilot (DMP) was monitored during flight. The results are presented in the 
following paragraphs. 
Biomedical instrumentation and physiological data.-All physiological measurements re- 
mained within the expected limits. Electrocardiographic and respiratory rate data were 
obtained through the bioinstrumentation data system during launch and on mission days 
2, 7, and 8 in conjunction with the exercise periods; additional data were obtained during 
the entry phase of the mission. Table 3-1 is a summary of the physiological data obtained 
from the biomedical instrumentation. 
tion electrodes resulted in poor quality data not suitable for analysis. Because of ground- 
support technical difficulties on mission day 6, no biomedical data were received in the 
Mission Control Center (MCC). Although 5 minutes of instrumented periods of rest, ex- 
ercise, and postexercise data were formally requested before flight, the lack of knowledge 
in real time of the exercise start and end times prevented correlation of the biomedical 
data with the actual activity periods. 
On mission day 2, interference of the DMP’s exercise harness with his bioinstrumenta- 
aNASA Lyndon B. Johnson Space Center. 
bTripler Army Medical Center, Honolulu, Hawaii. 
1 1  
THE APOLLO-SOWZ TEST PROJECT MEDICAL REPORT 
TABLE 3-I.-PHYSIOLOGICAL DATA SUMMRY 
Heart rate, beats/min Respiration rate, breaths/min 
ACDR DMP CMP 
Mission phase ACDR DMP CMP 
Av Peak Av Peak Av Peak 
~~~ ~ 
Launch 105 130 95 123 82 117 14 14 9 
aOrbital flight 
Mission day 2 74 90 (b) (b) 66 91 10 (b) 21 
‘Mission day 6 - - - - - - - - - 
Mission day 7 70 117 - - 94 137 22 - 26 
- - - 16 - Mission day 8 - - 74 , 140 
Entry 96 150 67 91 76 124 24 16 13 
a b l u e s  obtained during exercise. 
bPoor data. 
‘No biomedical data received. 
No medically significant arrhythmias were detected during this mission. Isolated pre- 
mature heartbeats were observed in all three crewmembers. The fact that the frequency and 
character of these prematurities remained consistent with data obtained previously during 
ground-based studies indicated that they were not related to  space flight. 
Adaptation to  weightlessness.-All three crewmembers experienced the now classical fullness- 
of-the-head sensation immediately after Earth-orbital insertion. This symptom was mild and 
did not interfere with the crew’s performance. The crewmembers commented that they did 
not experience sensations of nasal stuffiness or  sinus congestion. Head movements and mov- 
ing around the spacecraft did not intensify the fullness-of-the-head feeling and did not provoke 
symptoms of motion sickness. There were no instances of nausea, vomiting, disorientation, 
or loss of appetite. 
Crew transfers.-No significant problems with the in-flight docking module (DM) compression 
and decompression profiles were encountered during the mission. The DM control and life 
support system performances were normal. During transfers, the DM pressure was raised with 
nitrogen from 3.32 t o  6.56 N/cm2. During transfers 1, 2 ,  and 4, the Soyuz crewmen requested 
that nitrogen be added to  the atmosphere in the DM to decrease the percentage of oxygen 
(0,) seeping into the Soyuz spacecraft; thus the DM-Soyuz combined volume total pressure 
was increased by 0.27, 0.40, and 0.13 N/cm2, respectively. No corrective actions were required 
12 
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during manual or automatic crew transfer operations. During the transfer operations, 8.57 
kg of oxygen were used compared to 7.60 kg - _  predicted, and 6.21 kg of nitrogen were used 
compared to  6.38 kg predicted. 
At 52 hours 1 1 minutes ground elapsed time (GET), after reopening hatch 1, which 
had been closed for docking, the crew reported a strong acetone-like odor in the DM but 
could not find the source. The crew performed standard procedures to verify the accept- 
ability of the DM atmosphere, then initiated mixing of the two atmospheres to allow re- 
moval of the odor by the environmental control system in the command module (CM). 
After extensive ground-based studies, i t  was postulated that the odor was probably caused 
by methyl ethyl ketone, methyl isobutyl ketone, or both. These compounds are compo- 
nents in the glue used for lining the DM with Velcro material. There was no evidence of 
adverse effects to  crew health from exposure to  the compounds or  further reports of this 
odor. 
I 
Medication.-Table 3-11 is a list of the medications taken by each crewman during flight. 
TABLE 3-11 .-MEDICATIONS TAKEN DURING FLIGHT 
Medication ACDR DMP CMP 
Actifed (decongestant) 2 
Lomotil (antiperistalsis) 7 
Scopolamine-dext roamphe tamine 0 
Aspirin a2 
sulfate (anti-motion-sickness drug) 
aNumber not definitely established. 
On mission day 3, the ACDR notified MCC that he took three Lomotil tablets prophylactically 
in an attempt to decrease the frequency of in-flight bowel movements. He took another two 
tablets on mission day 4 because of a loose bowel movement and again took two Lomotil tablets 
prophylactically on mission day 8 before DM jettison. The DMP and the CMP took two Lomotil 
tablets each, prophylactically, on mission day 3. The CMP took one scopolamine-dextroamphet- 
amine sulfate tablet prophylactically immediately after orbital insertion and repeated the same 
dose approximately 5 hours later. 
tablets prophylactically to prevent possible ear blockage during the entry phase. Since no 
significant medical problems requiring specific treatment occurred during flight, the medica- 
tions used by each crewmember were minimal when compared t o  those used on the majority 
of previous space flights. No medications for sleep were taken at any time during the in-flight 
period. 
On entry day, approximately 1 hour after the sleep period, the ACDR took two Actifed 
13 
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Postflight Crew Health Status 
The following discussion of crew health status after flight includes an analysis of the 
effects of spacecraft atmosphere contamination. 
Recovery.-The U.S. crew was exposed to toxic gases (mostly nitrogen tetroxide (N2O4)) 
from inadvertent reaction control system (RCS) firings during the descent phase, 30 seconds 
after drogue deployment and at approximately 21: 15:07 G.m.t. (1 1: 15:07 a.m. Hawaii time) 
on July 24, 1975. The N,04 entered the CM through the cabin pressure relief valve, which 
was opened during the landing sequence. 
During the postlanding medical debriefing, the ACDR reported, “There was a yellowish- 
brown colored smoke which smelled like RCS. The smoke was so thick that I had a hard 
time seeing the other crewmembers or  the dials in front of me. The smoke cleared very fast.” 
Neither the DMP nor the CMP reported observing the yellow-brown smoke. 
Once the crew disabled the RCS, and following initial peak exposure, uncontaminated 
air was drawn into the cabin until landing occurred. Simultaneously, the lithium hydroxide 
(LiOH) scrubbers continued t o  absorb the nitrogen oxide mixture. 
(inverted) position, the ACDR unstrapped and fell down into the CM tunnel, hurting his 
right shoulder and elbow. He unstowed the oxygen masks and proceeded to  provide oxygen 
to  the crewmembers. Not until the spacecraft assumed stable I (upright) position, approxi- 
mately 3 minutes 30 seconds after landing, did the ACDR notice that the CMP’s mask was 
hanging on the side of his face and that he was unconscious. From the available history, 
it appears that the CMP was unconscious for approximately 50 seconds. In retrospect, it is 
thought that the exposure t o  toxic fumes possibly combined with effects of the feet being 
positioned lower than the head while in stable I1 position could have contributed to  this 
fainting episode. The CMP recovered promptly when his face mask was positioned properly 
and the oxygen flow was increased. 
was positioned, and the CM hatch was opened. This action contributed to  further improve- 
ment of the ventilation and removal of the noxious gases from the cabin. 
Approximately 40 minutes 50 seconds later (21 :58:44 G.ni.t.), the spacecraft was 
hoisted aboard the recovery vessel U.S.S. New Orleans, and the crew exited the CM at 22:05: 
04 G.m.t. When the hatch was opened, a humid and moldy smell emanated from the CM; 
there was no  detectable odor of the irritant gas. All the crewmembers appeared steady, 
slightly pale, and profusely diaphoretic. The first indication of exposure to  the gas came 
later during the hangar-deck ceremony when the ACDR requested oxygen for smoke inhala- 
tion; the exposure event was detailed during the postflight debriefing sessions also. These 
facts were further ascertained by playback of onboard voice and data tapes. 
At 2 1 : 18: 24 G.m.t., the spacecraft landed. While the spacecraft was still in stable I1 
Once in stable I position, the postlanding ventilation was activated, the flotation gear 
Spacecraft ___--- atmosphere toxicology.-Total time of crew exposure to  the oxidizer vapors was 
4 minutes 40 seconds, from thcaosure  of the RCS isolation valves until the crew donned 
oxygen masks after landing. The peak cabin concentration after the RCS was electrically 
disabled was estimated to be approximately 700 parts per million (p/m) of N O4 at a pres- 
sure of 101.3 kPa (1 atm) (Figure 3-1). The average oxidizer concentration from the out- 
side inlet to the cabin pressure relief valve was 2000 p/m, o r  4100 mg/m3. The peak cabin 
concentration resulted in an estimated average crew exposure of approximately 5 10 mg/m3, 
14 
CREW HEALTH 
1400 
12m.  
,E lo@. r 
m 
c' 
E 
8 
6 600. 
800. 
+ c 
V 
400. 
200. 
0 
l6O0 RCS disabled (55:08 GET) r '\. 
. 
I I  I I I I I 
224:54:00 55:OO %:MI 57:W 58:00 59:OO 225:WOO 
Average exposure 
250 p lm or 510 mglm3, 
for 4 min 40 s 
Suit compressor masks on 
Figure 3-1. Cabin Oxidizer Concentration Expressed as Parts per Million of 
Nitrogen Tetroxide at a Pressure of 101.3 kPa (1 atm) 
which is equivalent t o  approximately 250 p/m of N, 0, at 101.3 kPa (1 atm). These toxi- 
cological estimates were not available at the time of exposure. The final estimates of the 
actual toxic levels of N,O, were based on the analyses of the spacecraft LiOH canisters 
and the visual comparison of different color shades of N,O, and air mixtures (Figure 3-2). 
Initial recovery day physical findings.-Once in the Mobile Laboratories (MOLAB) aboard 
the primary recovery ship (PRS), the medical team proceeded with the medical debriefing. 
Oxygen was administered to all three crewmen for approximately 10 minutes. The vital 
signs that were recorded from the three crewmembers in supine position at approximately 
22:40 G.m.t. ( 1  2:40 p.m. Hawaii time) are as follows. 
Heart rate, 
Crewmember beats/min 
ACDR 
DMP 
CMP 
90 
60 
56 
Blood pressure, Respiration rate, 
systolic/diastolic, breaths/min 
mm Hg 
1 18/70 
125170 
130180 
16 
20 
14 
15 
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Because of time constraints, while the history of exposure to  toxic fumes was being 
reconstructed, the medical team proceeded with the routine recovery day (R + 0) protocols. 
l n e  ALUK, ' --,-.WIW llau A v l l ! J  an - 7  ,, chnr+ u. lvlc hlnnrl .___ dmwing _ _ _  and no radioisotope studies, underwent the 
full lower body negative pressure (LBNP) protocol, which was terminated 3 minutes early in 
the minus 50 mm Hg period because of a drop in his systolic blood pressure. 
was completed and, after a preliminary conference with the MCC surgeons at the NASA 
Lyndon B. Johnson Space Center (JSC), it was decided t o  stop all of the preplanned medical 
experiments with the exception of the clinical examinations as dictated by the circumstances. 
Table 3-111 contains details of the modified recovery day schedules. 
In general, the chief complaints consisted of burning of the eyes with profuse tearing, 
burning sensation and itching of the exposed skin surfaces which subsided shortly after the 
entry into the MOLAB, tightness of the chest, retrosternal burning sensation, and inability 
to  inhale deeply which led to  a nonproductive and nonspasmodic cough. The review of sys- 
tems was noncontributory. The three astronauts were in no acute distress and all were ori- 
ented to  time, persons, and place. The examination of the skin and mucosa was within 
normal limits. Slight plantar hyperkeratosis and fissuring were present. Examination of the 
eyes revealed the pupils to  be round, regular, and equal in size; their reaction to  light was 
within normal limits. Extraocular movements were intact, full, and equal. Visual fields and 
fundi were well within normal limits. Examination of the ears, nasal mucosa, and pharynx 
was unremarkable. The tracheas were midline and mobile. The shape and size of the thyroid 
glands were within normal limits. No cervical vein engorgement was noted; carotid arterial 
pulsations were equal, without bruit, and within normal limits. The chests were symmetrical 
with good expansion. Deep inspiration produced coughing. The lungs were clear to  percus- 
sion and auscultation. Examination of the cardiovascular system revealed normal sinus rhythm. 
There were no  murmurs, thrills, clicks, or evidence of cardiomegaly. There was no abdominal 
tenderness or  organomegaly, and the bowel sounds were within normal limits. Abdominal 
and lumbar paravertebral auscultation failed t o  reveal abnormal bruits or  murmurs. Genitalia 
and rectal examinations were unremarkable. Detailed neurological examination showed only 
slight fine tremor of the fingers. Slight hyperreflexia of the deep tendon reflexes was noted. 
Physical examination of the endocrine system was normal. The peripheral vascular system 
was intact. No peripheral lymphadenopathies were detected. Generally, the musculoskeletal 
system was within normal limits. 
The examination of the ACDR's right shoulder and elbow showed slight tenderness on 
palpation; there were no ecchymoses or limitations to  motion. The DMP exhibited a slight 
restriction of mobility of the lumbar spine and straightening of the lordosis. This condition 
was caused by a strain sustained while exercising during flight. He also had minor bruises 
over the right temporal region and the right patella. The recorded postlight vital signs, 
weights, heights,' and oral temperatures are shown in Table 3-IV. 
During the physical examination, following 5 minutes in the standing position, it was 
noticed that the CMP's systolic blood pressure dropped to 50 mm Hg with no  audible read- 
outs for the diastolic pressure. He was pale and complained of generalized weakness. The 
CMP was immediately returned to a supine position, and recovery from the orthostatic 
episode was uneventful. After 3 minutes in the supine position with elevation of the legs, 
his vital signs were: blood pressure, 122/68 mm Hg; heart rate, 60 beats/min; and respiration 
rate, 15 breaths/min. 
-. 
At approximately 23:20 G.m.t. ( 1  :20 p.m. Hawaii time), the full history of exposure 
'Importance of crew height measurements are detailed in Chapter 16. 
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TABLE 3-III.-MODIFIED MEDICAL SCHEDULES ON RECO VER Y DA Y 
Time, h:min Event 
G.m.t. Hawaii ACDR DMP CMP 
22:24 
22:35 
22:40 
22:45 
22:55 
23 : 02 
23:lO 
23: 15 
'23:20 
23:25 
23~30 
23:32 
23:40 
24:OO 
0o:w 
00: 24 
00:35 
00:50 
02:20 
02:50 
08:OO 
12:24 p.m. 
12:35 p.m. 
12:40 p.m. 
12:45 p.m. 
12:55 p.m. 
1 :02 p m .  
MOLAB + 0, 
Microbiology samples, 
exposure history, 
and vital signs 
obtained 
Blood drawing ini- 
tiated 
Leg measurements 
Height and weight 
measurement 
obtained 
Into C V  
MOLAB + 0, 
Exposure history 
and vital signs 
obtained 
MOLAB + 0, 
Exposure history, 
vital signs, and 
microbiology 
samples obtained 
- Microbiology samples 
started 
Blood drawing 
initiated 
Blood drawing 
initiated 
- 
Leg measurements 
- 
- 
PFT 
- 
Leg volume and EKCb : lop.m.  
: I 5  p m .  
:20 p.m. 
:25 p.m. 
:30 p.m. 
:32 p.m. 
Leg measurements 
- 
P F T ~  
Resting echocar- 
diography 
LBNF 
Early dump hypoten- 
sion SO/? mm Hg, 
no subjective 
symptoms reported 
EMG' 
Release from CV 
Shower 
1 :40'p.m. 
2:OO p m .  
- 
Shower 
- 
Shower 
2:09 p.m. 
2:24 p m .  
2:35 p.m. Chest X-rays, physi- 
cal exam, and EKG 
initiated 
- Chest X-rays, physical 
exam, EKG, and 
PFT initiated 
- 
2:50 p m .  
4:20 p.m. Chest X-rays, physical 
exam, and EKG 
initiated 
Rest in crew quarters 
and supper 
To PRS sickbay for 
sleep and observa- 
tion 
Rest in crew quarters 
To PRS sickbay for 
and supper 
sleep and observa- 
tion 
4:50 p.m. 
1O:OO p m .  
Rest in crew quarters 
To PRS sickbay for 
and supper 
sleep and observa- 
tion 
= cardiovascular laboratory. 
bEKG = electrocardiogram. 
d~~ = pulmonary function test. 
eTerminated 3 minutes early. 
'JSC conference with MCC surgeons regarding history of fEMG = electromyograph. 
exposure to N O4 and monomethyl hydrazine. Decision 
made to stop & postflight medical protocols. 
18 
CREW HEALTH 
TABLE 3-IV.-POSTFLIGHT PHYSIOLOGICAL PARAMETERS 
Blood piesyiie, 
Heart rate, Respiration rate, Weight, Height, Temperature, 
beats/min breaths/min kg cm "C ( O F )  systolic/diastolic, mm Hg 
Supine 
Sitting 
Standing 
Supine 
Sitting 
Standing 
Supine 
Sitting 
Standing 
88 
100 
100 
60 
60 
66 
60 
80 
88 
1 12/70 
11 1/72 
102/68 
1 12/70 
1 10170 
1 lO/SO 
122168 
108/78 
100/78 
ACDR 
14 
14 
16 
DMP 
- 
- 
20 
CMP 
16 
16 
16 
- 
77.7 
- 
72.8 
- 
77.6 
- 
182.6 
- 
180.5 
- 
180.5 
- 
35.7 (96.4) 
- 
- 
35.4 (95.8) 
- 
- 
36.0 (96.8) 
Chest roentgenograms done on all three crewmembers failed to  reveal any signs of  
pulmonary involvement (Figure 3-3). Electrocardiographic tracings were within normal 
limits and identical with baseline data. 
Subsequent Course of Events 
For the remainder of the evening of July 24, 1975, the crewmembers did not exhibit 
any significant change in general symptomatology. The feeling of chest tightness, retrosternal 
burning sensation, and cough on deep inspiration persisted without worsening. Following 
showers and supper, the astronauts were transferred, at 0800G.m.t. July 25, 1975 (10.00 p.m. 
Hawaii time July 24, 1975) to the sickbay of the ship for rest and further observation. 
Although they spent a relatively quiet night, sleep was interrupted by occasional episodes 
of coughing. None of the crewmembers complained of shortness of breath. 
On July 25, 1975 (day R + l ) ,  at 16: 10 G.m.t. (6: 10 a.m. Hawaii time), the astronauts 
were awakened for further clinical evaluation, consisting of blood draws and chest roentgen- 
ograms. The general physical examinations were unremarkable. When questioned about 
symptoms, all crewmembers complained of slight tightness of the chest and more pronounced 
inability to breathe deeply without coughing. In fact, they were unable t o  breath-hold and 
perform forced expiratory maneuvers required for repeat pulmonary function tests. The fol- 
lowing table represents the vital signs as obtained in the supine position. 
Followup chest roentgenograms were obtained at 18:OO G.m.t. ( 8 : O O  a.m. Hawaii time). 
Shortly after the chest X-rays were taken and while brushing his teeth, the DMP experienced 
slight shortness of breath, developed giddiness, and fainted. He was unconscious for about 
1 minute. There was slight twitching of the eyelids without evidence of seizure activity, and 
he recovered quickly when placed in the supine position. This episode was attributed to 
orthostatic intolerance. 
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Figure 3-3. Chest Roentgenogram Showing No Pulmonary Involvement 
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Blood pressure, 
mm Hg 
Heart rate, Respiration rate, 
beats/min breathslmin Crewmember systolic/diastolic, 
ACDR 
DMP 
CMP 
90 
64 
68 
108170 
122/58 
1 18/72 
16 
20 
20 
The repeat chest roentgenograms on all three crewmembers revealed the presence of 
diffuse, nodular-type infiltrates throughout both lung fields. A rosette-type pattern with 
occasional confluence of the infiltrates was present. Both costodiaphragmatic angles were 
clear with no  evidence of pleural effusion, Kerley B lines, o r  increased pulmonary vasculature. 
There was no  prominence of the pulmonary artery and no  signs indicative of the left or right 
heart involvement. These findings were suggestive of alveolar exudative fillings, characteristic 
of a diffuse chemical pneumonitis; an example is shown in Figure 3-4 of the same astronaut 
detailed in Figure 3-3. 
At 18:30 G.m.t. (8:30 a.m. Hawaii time), each astronaut was given 16 mg of dexametha- 
sone intravenously and then transferred to  Tripler Army Medical Center in Honolulu, Hawaii, 
for further medical care. 
Additional bedside chest X-rays, obtained at 20:45 G.m.t. (10:45 a.m. Hawaii timej, 
confirmed the diagnosis made aboard the recovery vessel. Arterial blood gases were sampled 
at room air at 21 :00 G.m.t. ( 1 1 :00 a.m. Hawaii time). The results are tabulated as follows, 
for partial pressure of oxygen (p02) ,  partial pressure of carbon dioxide (pCO,), and hydrogen- 
ion concentration (pH). 
Measuremen, ACDR DMP CMP 
p02,  mm Hg 76 90 70 
PCO,, mm Hg 37 28 43 
PH 7.41 7.48 7.43 
Repeated chest X-rays obtained at 01:OO G.m.t. July 26, 1975 ( 3 : O O  p.m. Hawaii time 
July 25, 1975) showed an increase of the infiltrates, more pronounced on the DMP's X-ray. 
Followup room-air arterial blood gas studies performed at 01 :30 G.m.t. (3:30 p.m. Hawaii 
time) are tabulated as follows. The blood gas findings were indicative of mild respiratory 
alkalosis with hyperventilation and hypoxemia. 
It was decided to switch t o  oral steroid therapy, consisting of daily doses of 80 mg of 
Prednisone. Because of the lack of symptomatology and the absence of cyanosis and/or 
signs of severe anoxia, oxygen was not administered. Vital signs remained stable, and there 
was no evidence of cardiac rhythm disturbances. 
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Figure 3-4. Chest Roentgenogram Suggestive of Alveolar Exudative Fillings 
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Measurement ACDR DMP CMP 
PO,, mm Hg 84 86 84 
PCO,, mm Hg 29 33 35 
PH 7.43 7.51 7.44 
I Hospital Course and Followup 
The astronauts were afebrile on admission and remained so throughout their hospitaliza- 
tion period. Vital signs remained generally within normal limits. No significant changes in 
postflight weights were observed (Table 3-V). 
I 
I 
1 TABLE 3-V.-PREFLIGHTAND POSTFLIGHT WEIGHT VARIATION 
Body weight, kg 
ACDR DMP CMP 
Day 
F-30  
F -  15 
F - 5  
F - 1  
F - 0  
R t O  
R t 1  
R + 2  
R + 3  
R t 4  
R t 5  
R t  13 
- 
x f SDa 
78.2 
78.8 
77.0 
78.2 
76.9 
77.6 
79.5 
78.9 
77.3 
77.3 
76.8 
79.5 
75.3 
76.0 
76.7 
75.7 
74.8 
72.8 
76.4 
76.5 
78.5 
80.0 
76.4 
78.2 
77.8 2 0.83 75.7 f 0.71 
81.0 
80.4 
79.8 
80.1 
80.2 
77.6 
81 .O 
80.6 
74.8 
76.9 
78.6 
82.2 
80.3 f 0.45 
aMean plus or minus standard deviation. 
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The crewmembers continued to have mild discomfort with deep inspiration. The 
discomfort gradually lessened. They became asymptomatic on July 27, 1975 (day R + 3). 
The chest X-rays returned to  normal on July 29, 1975 (day R + 5). The corticosteroids 
were gradually tapered and finally discontinued on August 2, 1975 (day R + 9). 
The crewmembers were discharged from the hospital on July 30, 1975 (day R + 6). 
A period of rest, reconditioning, and observation in Hawaii followed. Daily medical evalu- 
ations remained within normal limits. All the crewmembers participated in mild exercise, 
such as jogging, under medical supervision; they exhibited a gradual improvement in physical 
endurance. The crewmembers left Hawaii on August 7, 1975, and were returned to their 
regular duties. 
sure to N, 0, vapors. It was established that there were no obvious residual aftereffects 
from the exposure t o  toxic fumes. 
Followup detailed medical evaluations were performed 4 weeks after the initial expo- 
Clinical Laboratory Data 
Extensive laboratory studies were conducted to  determine the presence of N, 0, and/ 
or monomethyl hydrazine exposure. The laboratory findings are discussed in Chapters 14 
and 15. Because the nature of these toxic fumes was not completely known, it was decided 
to  perform several specific tests to  isolate the compounds mentioned. These tests included 
the search for Heinz bodies and for elevation of serum triglycerides, cholesterol, methemo- 
globin, and hydrazine levels. 
compared to the preflight levels. By day R + 1, the methemoglobin level had dropped t o  a 
mean value of 2.0 percent, not significantly different from preflight values. This finding is 
compatible with, but not pathognomonic of, exposure to  N,O, . There was no increase in 
the serum cholesterol and triglyceride levels or the presence of hydrazine or  Heinz bodies 
which would be indicative of monomethyl hydrazine inhalation. 
There was an initial elevation in the methemoglobin level (mean = 4.2 percent) at R + 0 
i 
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4. RESULTS OF PULMONARY FUNCTION TESTS 
I 
Arnauld E. Nicogossian? Charles F. Sawin,a and Peter J. Batellonib 
I Preflight pulmonary function tests were performed in conjunction with other medical 
I evaluations 45, 30, and 15 days before lift-off (F - 45, F - 30, and F - 15, respectively). 
Because of  hardware malfunction on day F - 45, data were not amenable to  analysis and 
only two sets of data were used for baseline purposes. Following exposure to  nitrogen 
tetroxide and 10 minutes prebreathing of 1 00-percent oxygen, pulmonary function screen- 
ing tests were obtained on all three crewmembers on recovery day aboard the prime recovery 
vessel. The quality of recovery day (R + 0) data was satisfactory, and no significant changes 
were observed when compared to  the preflight means. Followup evaluations were performed 
1 ,  2, and 13 days after recovery (R + 1, R + 2, and R + 13, respectively) at Tripler Army 
Medical Center and repeated on day R + 29 at the NASA Lyndon B. Johnson Space Center 
ciated with deep inspiration and breath holding on days R + 1 and R + 2, no satisfactory 
data could be obtained. In general, because of different types of hardware and techniques 
employed in these pulmonary function measurements, the obtained data were variable and 
interpretation was difficult. A slight decrease of timed expiratory flows was observed 1 day 
following recovery (day R + 1). Besides the already mentioned mild hypoxia and respiratory 
alkalosis (Chapter 3), the only significant finding was a decrease in the single-breath carbon 
monoxide diffusing capacity (DLCO, >. These findings were in agreement with the observed 
roentgenological abnormalities. The Jecrease in the diffusion capacity was more pronounced 
in the Apollo commander: less than 50 percent of the predicted value based on his age, 
weight, and height. This decrease in DLCOsB persisted until test day R + 13. The R + 29 
data obtained from the three crewmembers showed that the measured pulmonary function 
parameters, including DLCOs*B and repeat blood gas determinations (breathing room air and 
100-percent oxygen), were within normal limits. These data are summarized in Tables 4-1, 
4-11, and 4-111. 
I 
l and at Saint Luke’s Episcopal Hospital in Houston, Texas. Because of the discomfort asso- 
aNASA Lyndon B. Johnson Space Center. 
bTripler Army Medical Center, Honolulu, Hawaii. 
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TABLE 4-I.-APOLLO COMMANDER PULMONARY FUNCTIONS 
Parameter 
Preflight 
- sp R+O R + l  R + 2  R + 5  R t 1 3  R t 2 9  
RV (liters) 
CV (liters) 
VC (liters) 
TLC (liters) 
FVC (liters) 
FEV-1 (liters) 
FEV-1 
% 
FVC 
FVC % 
vc 
MEFR (l/sec) 
MMFR (l/sec) 
E% vc 
cc 
-% 
TLC 
DLCO,, (mlCO/min/mm Hg) 
2.53 f 0.12 
0.59 f 0.24 
5.38 f 0.10 
7.90 ? 0.17 
5.39 f 0.04 
3.83 ? 0.08 
71.1 f 1.07 
100.2 k2.16 
5.93 f 0.25 
2.83 f 0.12 
10.8 ? 4.26 
39.3 f 2.61 
2.0 (b) 
0.64 
5.45 3.72 
7.50 
5.13 3.67 
3.72 2.78 
72.40 75 
101.60 98 
5.70 5.41 
2.90 2.36 
11.70 (b) 
35.20 (b) 
(b) 
2.10 
5.10 
7.22 
4.80 
3.70 
76 
72 
5.9 1 
3.40 
7.5 
33 
5.55 
4.1 7 
75 
8.41 
3.63 
8.3Sb 14.58 
2.14 
5.60 
7.82 
5.56 
4.26 
76 
99 
9.50 
3.66 
14.48 
2.23 
0.93 
5.35 
7.55 
5.20 
3.75 
72 
97.3 
5.3 
3.0 
17.4 
41.9 
3 1.33 
aMean plus or minus standard deviation. 
bCrewman unable t o  perform maneuver. 
RV = residual volume 
CV = closing volume 
VC = vital capacity 
TLC = total lung capacity 
FVC = forced vital capacity 
FEV-1 = forced expiratory volume in one second 
MEFR = maximum expiratory flow rate 
MMFR = maximum midexpiratory flow rate 
CC = closing capacity 
DLCOsB = single breath carbon monoxide diffusing capacity 
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TABLE 4-II.-COMMAND MODULE PILOT PULMONAR Y FUNCTIONS 
Parameter Preflight 
x f SDa Rt.0 R + l  R + 2  R+5 R t 1 3  ~ + 2 9  - 
RV (liters) 
CV (liters) 
VC (liters) 
TLC (liters) 
FVC (liters) 
FEV-1 (liters) 
FEV-1 % -
FVC 
E% vc 
MEFR (l/sec) 
MMFR (l/sec) 
cv 
- %  vc 
K% 
TLC 
DLCOs, (mlCO/min/mm Hg) 
2.1 1 f 0.34 
0.53 +- 0.05 
5.1 1 ? 0.10 
7.23 f 0.35 
4.98 f 0.04 
3.91 f 0.31 
78.5 f6.16 
97.8 k3.50 
7.10 f 1.14 
3.93 f 0.38 
10.33 f 0.76 
36.43 f 3.17 
2.87 (b) 
0.93 
5.06 3.70 
7.90 
5.23 2.82 
3.69 2.10 
70.40 75 
103.4 76 
5.70 4.25 
4.20 1.61 
18.40 
48.10 
2.28 
5.02 
7.30 
4.57 
3.41 
74 
91 
6.8 1 
2.81 
13 
38 
15.09 
5.28 
4.1 2 
78 
8.33 
4.21 
24.87 
2.07 
5.20 
7.23 
5.16 
4.09 
79 
99 
9.23 
4.43 
29.55 
1.98 
0.85 
5.28 
7.26 
4.86 
3.95 
81.2 
92.8 
7.8 
3.7 
16.1 
39 
41.13 
aMean plus or minus standard deviation. 
bCrewman unable to perform maneuver. 
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TABLE 4-III.-DOCKlNG MODULE PILOT PULMONAR Y FUNCTIONS 
Parameter R+O R + 1  R + 2  R t 5  R + 1 3  R + 2 9  Preflight x f SDa 
- 
RV (liters) 
CV (liters) 
VC (liters) 
TLC (liters) 
FVC (liters) 
FEV-1 (liters) 
FEV-1 % 
FVC 
E% vc 
MEFR (llsec) 
MMFR (I/sec) 
cv - %  vc 
cc - 70 
TLC 
DLCO,, (mlCO/min/mm Hg) 
2.47 f 0.42 
0.78 f 0.33 
5.51 f 0.02 
7.97 f 0.4 
5.41 f 0.05 
4.01 f 0.02 
74.1 f 1.01 
98.2 f 1.35 
8.33 * 0.38 
3.07 _+ 0.06 
14.1 f 5.86 
40.7 f 3.78 
2.57 2.46 2.96 (b) 2.35 
0.39 0.55 
5.50 5.11 5.25 5.83 5.58 
8.50 7.87 8.41 8.04 
5.42 4.56 5.25 5.69 5.83 5.64 
3.92 3.58 3.32 4.48 4.40 4.15 
72.20 78 63 79 75 73 
98.70 89 1 00 100 100 
8.00 9.13 8.51 11.45 7.63 8.7 
2.80 3.21 1.51 4.03 3.51 3.0 
7 .OO 9 9.9 
39.60 34 37.4 
16.37 20.15 28.22 29.23 
aMean plus or minus standard deviation. 
bCrewman unable t o  perform maneuver. 
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5 .  IN-FLIGHT RADIATION DETECTION 
J. Vernon Baileya 
RADIATION DOSIMETRY 
One personal radiation dosimeter (PRD) and one passive dosimeter (PD) each were 
assigned to and were worn at launch by the Apollo commander (ACDR), command module 
pilot (CMP), and docking module pilot (DMP). During the mission, the PD’s assigned to  
the ACDR and the DMP were worn in the left leg pocket of the in-flight coveralls, and the 
PD assigned to  the CMP was worn in the left thigh pocket. All flight dosimeters were re- 
covered and returned to  the NASA Lyndon B. Johnson Space Center (JSC) for evaluation. 
PASSIVE DOSIMETERS 
The flight PDs  were disassembled, and the component detectors were forwarded to  the 
cognizant analysts. The thermoluminescent dosimeters were analyzed in the Lockheed 
Radiation Laboratory, and the results are reported following this paragraph. The nuclear 
emulsions were forwarded to Dr. H. J. Schaefer at the Naval Aerospace Research Laboratory, 
and preliminary results are reported following the next paragraph. The neutron resonance 
foils and the Lexan track detectors were forwarded t o  Dr. J. S. Clark, JSC, and Dr. E. V. 
Benton, University of San Francisco, respectively. The control PD confirmed that no extra- 
neous prelaunch radiation occurred. No evidence of contamination or  component damage 
was observed during disassembly of the dosimeter. The PD results from the thermolumi- 
nescent dosimeters are as follows. 
Serial no. 
1077 
1078 
1079 
1087 
Assignment 
ACDR 
CMP 
DMP 
Control 
Mission dose, 
mrad 
llOt 1 1  
108+ 1 1  
100 f 10 
< I  
~~ 
aNASA Lyndon B. Johnson Space Center. 
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A preliminary analysis of the nuclear emulsions based on photodensitometer measure- 
ments and ratios of those measurements to proton doses determined from the previous 
Apollo Earth-orbit mission agreed well with the thermoluminescent dosimeter data. These 
results are as follows. 
Emulsion Proton dose (estimated), 
pack no. Assignment mrad Serial no. 
1077 1B ACDR 
1078 2B CMP 
1079 3B DMP 
102 
99 
90 
The track and grain count analyses are being continued to  provide a more accurate 
measurement of the Apollo-Soyuz Test Project (ASTP) crew dose from the trapped radia- 
tion environment. 
PERSONAL RADIATION DOSIMETERS 
Personal radiation dosimeter (PRD) postmission response testing was performed at  
JSC. The PRD battery voltages were measured before this testing was begun. Battery 
voltages on all three PRD’s exceeded 10.70 V dc; 9.0 V dc was the required minimum for 
satisfactory operation. Premission and postmission responses were compared and are 
essentially identical. At a dose level of 0.93 mrad/h, personal radiation dosimeter 1022HRE 
and 1037HRE responses were minus 6 percent, and PRD 1025HRE response was minus 12 
percent. At all data points above 2.0 mradlh, the response deviations for all three instru- 
ments were zero percent. Therefore, the following mission doses reported are splashdown 
values with n o  response corrections. The tolerance shown represents the one-register-count 
(0.01 rad) uncertainty inherent to digital readouts. 
Mission dose, 
rad Serial no. Crewman 
ACDR 1022HRE 0.15 ? 0.01 
CMP 1025HRE 5.58 
DMP 103 7HRE .12 ? .01 
The in-flight malfunction observed on PRD 1025HRE was not reproduced during the 
postmission testing. One register count (0.01 rad) was accumulated during the 4.5 days 
between splashdown and initiation of postmission testing. However, this deviation is normal 
IN-FLIGHT RADIATION DETECTION 
and within design specifications. The 30 to 40 counts per day accumulated during the 
mission indicated either a gate-to-drain leakage of the electrometer (MOSFET) or  loose 
cznducthe partic.!es in the ion chamber. However, neither condition would account for 
the 144 counts registered between the last in-flight reading and the splashdown reading. 
An intermittently open circuit could, during entry buffeting, register counts at a very 
high rate and might also account for the day-to-day counting observed. Since this PRD 
operated normally during the Apollo 10, Apollo 15, and Skylab 3 missions, the condition 
resulting in the ASTP malfunction probably occurred just before, or  during, launch. Two 
dents in the aluminum housing (on one corner and one edge), not present during preinstall- 
ation acceptance testing, were observed when the dosimeter was returned to  JSC. The 
dents indicated that the instrument had been dropped and/or struck. 
SUMMARY 
The three P D s  and two of the PRD’s operated satisfactorily throughout the mission. 
Because n o  future mission support is anticipated for these PRD’s, failure analysis of the 
PRD malfunctioning during the zero-g portion of this mission is not planned currently. 
The 10 to 15 mrad/day crew exposures reported for the ASTP PRD’s and PD’s are among 
the lowest reported for any Apollo mission and approach the minimum response sensitivity 
of the PRD’s. The total space radiation exposure of the ASTP crewmen is insignificant 
from a medical standpoint. 
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6. FOOD AND NUTRITION 
Malcolm C. Smitha and Rita M. Rappa 
IWTRIENT ENERGY REQUIREMENTS DETERMINATION 
As a result of Apollo and Skylab experimentation, data now exist showing relation- 
ships between ground-based and in-flight energy requirements. It is recognized that the 
best estimates of ground-based energy requirements are made on the basis of lean body 
mass (LBM); i.e., muscle mass. Accurate determination of LBM may be obtained from a 
total body count of gamma radiation emitted by the body’s natural burden of potassium- 
40 (40 K). 
the potassium content of LBM is nearly constant and that body fat is essentially free of 
potassium. In this context, the body is considered to  be composed of two compartments, 
the fat compartment and the fat-free LBM compartment. 
Since 0.01 19 percent of all naturally occurring K is the radioactive isotope 40K, a 
measure of this isotope is an indirect measure of the total K. The whole-body counter 
measures 40K. Total K is calculated and LBM is determined by use of appropriate con- 
stants. 
It was anticipated that the average daily in-flight energy intake in the Apollo-Soyuz 
Test Project (ASTP) would fall short of Skylab intakes and would more closely approximate 
the averages observed during Apollo flights (i.e., approximately 29 kcal/kg/day) because of 
the brevity of the mission and the failure to achieve metabolic stabilization. For this reason, 
certain nutrients, in particular sodium (Na) and K, were concentrated in those foods for 
which the crew displayed the highest preference and which were deemed most likely t o  be 
consumed. As much as possible of the minimum nutrient requirements were included in a 
basic diet of approximately 1800-2000 kilocalories (kcal). Despite these measures, an aware- 
ness of the true energy demands should be kept in mind for understanding the degree of 
metabolic deficiency that was incurred. 
ground radiation counting facility a t  the NASA Lyndon B. Johnson Space Center after 
appropriate calibration with similar counting facilities at U.S. Air Force School of Aviation 
Medicine and at Battelle N.W. Laboratories. Additional calibration in the technique was 
accomplished using 42K. Potassium-42 has a 12.36-hour half-life and emits beta rays having 
a maximum energy of 3.52 MeV and a gamma ray having an energy of 1.525 MeV. The 
gamma ray energy is close enough to  that of 40K ( 1.46 MeV) to  enable direct comparison 
of the photopeak areas for calibration purposes. For calibration, the same amount of 42K 
ingested by the volunteer is placed in a 500-ml bottle, and the bottle is filled with water. 
A weighed quantity of potassium nitrate (KNO,) is placed in the same size bottle and dis- 
solved in water, and the solution is diluted t o  the same volume as the 42K solution. Counting 
The whole-body counter method of determining LBM is based on the assumption that 
Lean body mass was determined by measurement of total body 40K in the low-back- 
aNASA Lyndon B. Johnson Space Center. 
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measurements are made with the whole-body counter on each of the bottles and the vol- 
unteer using the following relationship. 
counts per gram K in body 
counts per gram K in bottle 
counts of 42K in body 
counts of 42K in bottle 
- 
The calibration factor can be derived using the following equation. The equation is 
independent of the exact quantity of 42K but dependent on the weight of K in the bottle, 
which can be determined very accurately. 
Counts per gram K in the body = Counts per gram K in bottle 
counts of 42 K in body 
counts of 42K in bottle 
X =  
A 30-minute count was made on each subject. Before and immediately after counting 
each subject, a 5-minute count of background and a 5-minute count of a 2.3-kg (5 lb) bottle 
of crystalline potassium chloride (KC1) were made. The periodic count of KC1, a reference 
source,’was used to correct any variation in overall counter efficiency. Averages were obtained 
for these counts, corrected for background, and the counts were then reduced t o  counts per 
second. 
niques depend on the weight of the subject. The single mathematical expression logl, (8) = 
A + B (Wkg) will fit the curve of calibration factors obtained for subjects whose weights 
range from 43.88 kg to 157 kg. The actual calibration factor found for a particular subject 
may differ by as much as 10 percent from the value predicted by the regression line. The 
exchangeable K content of the body, as measured by the isotope-dilution technique, is very 
close to  92 percent of the total body K for all active subjects, including those who have starved 
for several weeks and lost considerable weight. The results of LBM determinations performed 
on the prime crewmembers are as follows. 
I t  has been demonstrated that the calibration factors for all whole-body counter tech- 
Subject Body weight, 
kg 
LBM , 
ks 
Apollo commander (ACDR) 78.30 142.33 61.78 
Docking module pilot (DMP) 76.05 166.43 65.14 
Command module pilot (CMP) 81 .oo 190.54 70.95 
The measurements were made on December 2 and 3, 1974. For comparison, the total 
exchangeable K estimated by the 42K exchange technique for the Skylab crewmembers is 
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given in Table 6-I.172 Lean body mass measurements, derived from data on total exchange- 
able K, have been used as a basis for expressing caloric expenditure in Skylab crewmembers. 
1 ne resuits of these ~~ix i ip~ t i i t i~ i i s  irc shewn in Table 6-11. !t c m  be reen, t h ~ r ~ f n r e ,  that 
the Skylab crewmembers had a caloric intake at  a level of 45.68 f 4.50 kcal/kg/day. Based 
on in-flight changes in total body weight, muscle mass, and body volume, it appears that an 
average daily energy intake of 49.0 f 3.5 kcal/kg/day would have resulted in negligible body 
weight loss in Skylab crewmembers. 
the energy required to  maintain LBM during the ASTP mission was predicted. The results 
of this prediction are shown in the following table together with estimated energy based on 
subjective evaluation by the individual of his menus. (Changes in crew body weights are 
also included.) 
rm 
On the basis of Skylab energy consumption data and ASTP total body K measurements, 
Predicted energy consumption 
based on - Average in-flight 
Subject energy intake, 
Body mass 40K, Menu test, kcallday 
kcallday kcallday 
ACDR 
CMP 
DMP 
2822 2790 2900 
3241 2913 3000 
2975 3245 2867 
In-flight body 
wt change, 
kg 
-0.45 
-2.52 
-2.90 
IN-FLIGHT FOOD 
Flight menus were designed to  meet comparable individual energy requirements under 
normal gravity conditions, specified nutrient levels, and crew-selected preferred foods. 
Energy requirements calculated for each crewman were 281 5, 2760, and 2554 kcal/day for 
the ACDR, the CMP, and the DMP, respectively. Based on crew menu acceptance, evalua- 
tions, and compatibility tests, an average daily caloric intake of 2820 kcal was provided for 
the ACDR and the CMP, and 3 165 kcal was provided for the DMP. Estimates of in-flight 
food consumption based on daily reports indicate that averages of 2900, 3000, and 2867 
kcallday were consumed by the ACDR, the CMP, and the DMP, respectively. 
either calcium lactate or potassium gluconate. Calcium (Ca) fortified beverages were limited 
to two per man per day, whereas only one K-fortified beverage was required for each 4-day 
menu cycle. 
To meet the specified daily nutrient levels, some of the beverages were fortified with 
'Carolyn S. Leach and Paul C. Rambaut: Biochemical Responses of the Skylab Crewmen: An Overview. Ch. 23 of 
'Philip c. Johnson, Theda B. Discon, and Adrian D. LeBlanc: Blood Volume Changes. Ch. 26 of Biomedical Results 
Biomedical Results from Skylab, NASA SP-377, in press. 
from SYlab. NASA SP-377, in press. 
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TABLE 6-L-TOTAL EXCHANGEABLE POTASSIUM IN 
SK YLAB CREWMEMBERS 
Subject 
3208 ?r 114 
3870 f 105 
3782 f 133 
3245 f 133 
3045f 23 
4565 f 114 
3195k 56 
3569 f 165 
3517 f 200 
a Mean plus or minus standard deviation. 
TABLE 6-II.-SKYLAB IN-FLIGHT ENERGY INTAKE 
Energy intake 
LBM, 
kg kcallday kcall kglday Subject 
57 .O 
66.9 
71.4 
58.2 
53.6 
73.4 
57.3 
62.2 
62.5 
2616 
2746 
2606 
2636 
2581 
3543 
2959 
2850 
303 1 
45.89 
41.05 
36.50 
45.29 
48.1 5 
48.30 
51.64 
45.82 
48.50 
a45.68 f 4.50 
a Mean plus or minus standard deviation. 
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The crew selected a 4 d a y  menu cycle as used previously on Apollo missions rather 
thar. the 6-day cycle used during Skylab missions. The average daily nutrient intakes for 
the proposed and estimated in-flight food consumption for each crewrriiiii are shown ir. 
Table 6-111. 
TABLE 6-III.-A VERAGE DAILY NUTRITIONAL INTAKE 
Energy, Protein, Calcium, Phosphorus, Sodium, Potassium, Magnesium, Crewman 
kcal g mg mg mg mg mg 
Proposed intake 
ACDR 2820 99.7 1076 1832 4983 2942 313 
CMP 2820 98.1 1458 1996 4724 2984 288 
DMP 3165 112.2 1375 21 13 6402 3745 355 
Estimated actual intakea 
ACDR 2900 98.0 1295 1830 4970 2983 299 
CMP 3000 101.9 1661 207 1 5318 2975 290 
DMP 2867 107.7 1422 1964 6079 3748 322 
a Average of 7 nominal days; incomplete days have been omitted. 
In addition to the scheduled meals, a pantry containing beverages and snack foods 
was supplied. These foods could be used t o  substitute or  supplement the normal meal 
items. 
irradiated breakfast rolls; thermostabilized/irradiated turkey, corned beef, and charcoal 
broiled steak; thermostabilized cranberry sauce; tuna and salmon in cans which required a 
can opener; commercial cookies and graham crackers; dehydrated beef patty, pears, and 
potato patty; intermediate moisture almonds and cheese slices; and dried beef jerky. 
In general, the crew was satisfied with the quality and quantity of  flight food pro- 
vided. No gastrointestinal problems were encountered during the mission. Appetites during 
flight were reported t o  be the same as during the preflight period. The CMP reported 
changes in the taste of foods during flight and indicated that salty foods tasted best to  him. 
As on previous Apollo missions, the crew reported gas in the hot water supply which inter- 
fered with complete rehydration of the food. Throughout the mission, high-priority activ- 
ities and work schedules frequently precluded adequate time for meal preparation and food 
consumption. 
New food for this mission included dehydrated compressed pea bars and spinach bars; 
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7. POTABLE WATER 
Richard L. Sauera 
Postflight comments from the crew indicated that the potable water was of good 
quality. No out-of-specification conditions were noted in the microbiological and chem- 
ical analyses conducted. 
measured 2 hours later was sufficient for microbial control. 
problems were experienced. As in previous flights, some gas was present, particularly in 
the hot water. 
Postflight analyses indicated a lack of residual chlorine in the potable water. This 
deficiency remains unexplained since the records indicate that the last in-flight chlorination 
was accomplished 17 hours before landing. Chemical analyses of postflight samples showed 
all levels within specification limits. Microbiological results were positive for Flavobacterium 
species at levels of 10’ microorganisms/ml. 
Preflight chlorination was accomplished 19 hours before launch. The level of chlorine 
In-flight chlorinations were accomplished approximately on schedule, and no in-flight 
“NASA Lyndon B. Johnson Space Center. 
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8. FLIGHT CREW HEALTH STABILIZATION PROGRAM 
james K. Ferguson2 
The Flight Crew Health Stabilization Program (FCHSP) was activated for the 
Apollo Soyuz Test Project (ASTP) as outlined in the program document. Prime and back- 
up crewmen were held under conditions of semi-isolation from 2 1 days before flight until 
launch. Living quarters were established onsite at the NASA Lyndon B. Johnson Space 
Center (JSC) for both the prime and backup crewmen. The existing crew quarters at the 
NASA John F. Kennedy Space Center (KSC) were used while the crewmen were at that 
facility. 
lance Office 90 days before lift-off. All physical examinations for persons on this list were 
completed on schedule. Surveillance of the health status of primary contacts began on 
June 2, 1975, and continued through July 24, 1975, for a total of 53 days. The total 
number of primary contacts under surveillance reached 38 1. The number and location of 
the primary contacts are as follows. 
An identification list of primary contacts was made available to  the Medical Surveil- 
JSC KSC Other Total 
313 32 36 381 
Active surveillance was provided at the primary work areas during the times when 
crewmen were present in the areas. Throat examinations and temperature checks were 
made once daily on each primary contact entering the primary work area. The results of 
this active surveillance are shown in Table 8-1. 
TABLE 8-I.-ACTIVE SUR VEILLANCE OF PRIMAR Y CONTACTS 
Category JSC KSC 
Contacts examined (total) 1169 203 
Examining days 16 12 
Average daily examinations 73 16.9 
Contacts referred to clinic 5 1 
aNASA Lyndon B. Johnson Space Center. 
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The primary contacts reported their illnesses and exposure to  illnesses to the Medical 
Surveillance Office. All reporting was made on a voluntary basis. The number and location 
of the primary contact reports were as follows. 
Reports JSC KSC Other Total 
Illness 28 8 0 36 
Contacts to illness 7 1 0 8 
The rate of illnesses reported by the primary contacts was 12.4 illnesses per 1000 
persons per week. The rate of contacts to  illness reported was 3 per 1000 persons per week. 
The types of illness and exposures to  illness reported by the primary contacts are shown in 
Tables 8-11 and 8-111, respectively. 
TABLE 8-II.-TYPES OFILLNESSES REPOR TED BY PRIMARY CONTACT 
Symptom complexa JSC KSC Percent total 
Upper respiratory infection (URI) 
Bronchitis 
Pneumonia 
Upper enteric illness 
Lower enteric illness 
Fever present 
Headache present 
Skin infection present 
Other infectious illness 
23 
3 
0 
1 
0 
2 
4 
0 
1 
81 
8 
0 
3 
0 
6 
11 
3 
6 
a One illness may contain more than one symptom complex. 
The FCHSP was successfully completed with the recovery of the crewmen at the close 
of the mission. No infectious illness occurred in any of the crewmen during the period of 
time they were covered by the program. 
It was necessary for the crewmen to  enter a nonprimary work area during the preflight 
period for the purpose of obtaining additional suit-fit checks, for tests, and for the use of 
medical test equipment. In each case, however, the contingency plans were followed and no 
problems were encountered. 
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TABLE 8-III.-EXPOSURES TO ILLNESS REPORTED BY PRIMAR Y CONTAClX 
Illness contacted JSC KSC Percent total 
URI 
Chicken pox 
Mumps 
Impetigo 
1 0 
1 0 
2 0 
0 I 
13 
13 
25 
13 
Typhoid fever 1 0 13 
Infectious hepatitis 2 0 2s 
The rate of primary contact reporting of illnesses appeared to  be improved over past 
missions. For example, the ASTP summer mission had a greater number of illness reports 
(1  2.4 per 1000 per week) than was observed in the fall and winter missions of the Skylab 
Program (average 8.2 per 1000 per week). However, the reporting of the contacts to  
illness remained approximately the same as on past missions; the upper respiratory illness 
was predominant and represented 81 percent of the total illnesses reported. 
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SECTION I11 
PREFLIGHT, IN-FLIGHT, AND POSTFLIGHT MEDICAL TESTING 

9. ACHILLES TENDON REFLEX 
Eduard C. Burcharda and Arnauld E. Nicogossiana 
Generalized hyperreflexia was reported following long-duration Skylab orbital mis- 
sions. Because it was expected that changes in the neuromuscular function would occur 
even after a short-duration space flight, a decision was made to measure the Achilles 
tendon reflex duration in conjunction with the Apollo-Soyuz Test Project (ASTP) mission. 
METHOD AND MATERIAL 
The measurement of the Achilles tendon reflex time was performed during the phys- 
ical examination on all three prime astronauts 30 days before lift-off (F - 30), 15 days 
before lift-off ( F  - 1 9 ,  and on recovery day (R + 0) using a Burdick FM-1 photomotograph. 
A technique using a photoelectric cell is employed to  time the Achilles tendon reflex by 
measuring the displacement of the foot. A lamp and condensing lens in one side of the 
U-shaped housing directs a beam of light onto a photovoltaic cell on the opposite side of 
the housing (Figure 9-1(a)). With the subject kneeling comfortably on a specially designed 
chair, the unit is positioned so that the light beam is partially intercepted by the metatarsal 
region of the foot (Figure 9-1(b)). 
Figure 9-l(a). Photomotograph. Sketch of the Device 
aNASA Lyndon B. Johnson Space Center. 
47 
THE APOLLO-SOWZ TEST PROJECT MEDICAL REPORT 
Figure 9-l(b). Photomotograph. Positioning of the Device 
A tap on the Achilles tendon with a percussion hammer causes the foot to  move in 
the light beam and thereby to  generate a change in photocell voltage. The change in volt- 
age is recorded on electrocardiograph paper to  give a time-position plot of reflex action. 
For each test, an average number of 10 complexes on a strip chart is analyzed using a 
photomotogram scale (Figure 9-2). To determine the duration of the reflex response, 
measurements are made from the beginning of the hammer tap t o  one-half the relaxation 
period. 
RESULTS 
Table 9-1 and Figures 9-3 and 9-4 contain the Achilles tendon reflex data for the 
Apollo commander (ACDR) and the docking module pilot (DMP) from tests performed 
on days F - 30, F - 15, and R + 0. Four preflight baseline sets of data were obtained on 
the command module pilot (CMP) because he had had previous tests on July 24 and 
October 10, 1973, while performing as backup crewman for Skylab missions 3 and 4 
(Figure 9-5). 
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Peak contraction r 
Hammer tap- -. 
_c_ 
Hammer tap to 112 relaxation 
Figure 9-2. Photomotogram Tracing. The Horizontal Distance 
from Hammer Tap to One-Half Relaxation is Measured 
in Milliseconds 
TABLE 9- 1 .-ACHILLES TENDON REFLEX DATA 
Reflex time, ms 
Skylab ASTP 
Crewmember July 24, 1973 Oct. 10, 1973 F - 3 0  F - 1 5  R + O  
ACDR - - 298 304 280 
DMP - - 399 3 54 312 
CMP 317 340 303 29 1 299 
The Achilles tendon reflex was measured within 2 hours after recovery and after the 
ASTP astronauts had entered the operational Mobile Laboratory (Figure 9-6). The ACDR 
and the DMP exhibited a shortening in the reflex duration time (Table 9-1), whereas the 
CMP showed an increased reflex time when his datum was compared with his last preflight 
results. In addition to  the noted changes in reflex time, all three crewmembers showed 
significant fine tremor, as documented by tracings (Figure 9 - 9 ,  which could reflect the 
effects of the inhaled vapor of nitrogen tetroxide. This tremor which was recorded on 
the baseline tracings of the Achilles tendon reflex was also clinically observed in the fingers 
for a short time on R + 0. 
49 
THE APOLLO-SOWZ TEST PROJECT MEDICAL REPORT 
I I 
(a) 
Figure 9-3. Achilles Tendon Reflex Time, Apollo Commander 
(a) Preflight, F - 30 
(b) Postflight, R + 0 
Figure 9-4. Achilles Tendon Reflex Time, Docking Module Pilot 
(a) Preflight, F - 30 
(b) Postflight, R +  0 
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Figure 9-5. Achilles Tendon Reflex Time, Command Module Pilot 
(a) Preflight, F - 15 
(b) Postflight, R + 0 
E 
200 I I I I I 
Skylab 3 Skylab 4 ASTP ASTP ASTP 
(backup) (backup) F - 3 0  F - 1 5  R + O  
Test day 
July 24, 1973 Oct. 10, 1973 
Figure 9-6. Achilles Tendon Reflex Measurements of ASTP U.S. Crewmen 
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CONCLUSION 
The data show the predicted postflight change in the Achilles tendon reflex time; 
also, for the first time since the tendon reflex measurement was introduced, postflight 
tremor was documented. Further clinical studies will be required t o  determine whether 
the occurrence of such tremors is related to  exposure to  toxic material. 
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10. ELECTROMYOGRAPHIC ANALYSIS O F  SKELETAL MUSCLE 
Earl V. LaFevers,a Arnauld E. Nicogossian,” 
William N. Hursta) and Joseph T. Bakerb 
The first opportunity to  study the effects of long-duration weightlessness on human 
skeletal muscle function occurred during the Skylab missions. The results of the Skylab 
assessments provided ample evidence that normal muscle function is altered by periods of 
weightlessness of 59 days or more. This conclusion is supported by a number of physio- 
logical and biochemical changes that occurred during Skylab missions (ref. 10-1). The 
results of ground-based studies have shown that these changes are related t o  abnormal 
muscle function (refs. 10-2 to  10-7). For example, in the Skylab crewmen, tension capa- 
bility was decreased after flight. The electromyogram (EMG) spectral characteristics 
showed states of muscle superexcitability and increased fatigability with gradual return 
to  baseline states (ref. 10-8). 
The purpose of this study was to  investigate changes in skeletal muscle electrical 
activity that occur after exposure to short-term weightlessness; i.e., less than 10 days. 
The following changes were hypothesized. 
power into higher frequencies 
1. Heightened excitability as evidenced by a significant shifting of the spectral 
2. Reduced muscle electrical efficiency 
3.  Increased muscle fatigability when the muscles are subjected t o  a moderate 
fatigue-inducing stress. 
METHOD AND MATERIALS 
Instrumentation 
A skeletal muscle stress apparatus was designed and built to  enable controlled iso- 
metric muscle testing and measurements. A two-channel EMG detector was built to record 
the EMG. All data were recorded at a rate of 9.52 cm/s  (3.75 in/s) on magnetic tape by 
a four-channel recorder. A four-channel strip-chart recorder was used to  monitor the data 
playback from the magnetic tape during the experiment. 
Protocol 
Data were obtained on 3 preflight days: 45, 30, and 15 days before lift-off. Surface 
electrodes were placed on the lower leg muscles (gastrocnemius and soleus) and on the arm 
muscles (biceps brachii and brachioradialis). Seated in the muscle stress apparatus, the 
crewman was instructed t o  exert a series of graded efforts as follows. 
aNASA Lyndon B. Johnson Space Center. 
bTechnology Incorporated, Houston, Texas. 
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1. 10 seconds at 10-percent maximum voluntary contraction (MVC), 20 seconds rest 
2. 10 seconds at 20-percent MVC, 20 seconds rest 
3. 10 seconds at 30-percent MVC, 20 seconds rest 
4. 60 seconds at 50-percent MVC (leg) and 40-percent MVC (arm). 
Leg measurements and arm measurements were collected sequentially. Postflight only 
(recovery day) data on one astronaut were obtained. 
Data Processing 
A computer program, EMGAN, was written to  process the force and EMG data.' 
Force data were calibrated into pounds and averaged over 1-second intervals. The EMG 
signals were analyzed in 4-second segments. The data were calibrated into microvolts, and 
the integrated value for each segment was found. The discrete Fourier transform was used 
to  calculate the magnitude of the power spectral density. 
Muscle Excitability 
Skeletal muscle disuse attributable to  9 days of space-flight weightlessness resulted in 
increased excitability of the instrumented muscles of this study. Stressed at 30 percent of 
MVC, the gastrocnemius and biceps brachii muscles showed a postflight increase in their 
predominant frequency of 30 Hz (25 percent) and 20 Hz (40 percent), respectively. Before 
the flight, the soleus muscle showed an increase in predominant frequency amounting to  
30 Hz (25 percent). The brachioradialis muscle showed the least excitability effect from 
weightlessness. 
Muscle Electrical Efficiency 
The ratios of integrated electromyogram (IEMG) to  force for both the gastrocnemius 
and brachioradialis muscles showed a decreased level of electrical efficiency as a result of 
the 9 days in weightlessness; the data for the biceps and brachioradialis muscles show a 
tendency for increased electrical efficiency. All of the muscles, with the exception of the 
gastrocnemius, showed a decrease in the level of the IEMG after flight, and all of the muscles 
showed a progressive increase in electrical activity with increasing contraction force both 
before and after flight. The IEMG-to-force ratios for the 1 -minute fatigue-inducing stress 
showed the tendency for all the muscles t o  decrease in efficiency as the stress was maintained. 
The soleus muscle showed the greatest change in efficiency as a result of the 9 days in weight- 
lessness. 
Muscle Fatigabi I ity 
Analyses of variance were conducted on the power spectral data of the four muscles 
used in this study. Three main effects were considered in the analyses. 
W. N. Hursta: EMCAN: A Computer Program for Time and Frequency Domain Reduction of Electromyographic Data. 
Special report, Technology lnc., Sept. 1975. 
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1. Conditions, preflight compared to postflight 
2. Time increments; i.e., the four equally spaced time intervals within the 1-minute 
continuous isometric hold for which the EMG was spectrally analyzed 
3. Frequency bands used for the data analysis 
a. Leg muscles, 10 to  60 Hz in 1 0-Hz increments 
b. Arm muscles, 10 to  30 Hz in IO-Hz increments 
Significant shifting of the power spectra into lower frequencies was considered evidence 
of muscle fatigability. In the leg muscle, there was a significant difference between preflight 
and postflight spectral power levels; the postflight data showed a significantly greater pro- 
gressive power shift into the lower frequencies as a result of the 1-minute isometric stress. 
The arm muscles did not exhibit significant differences between conditions. 
CONCLUSIONS 
The present investigation of skeletal muscle function involving both leg extensor and arm 
flexor muscles in a shorter period of exposure to  weightlessness (9  days) has shown that the 
muscle dysfunction characteristics prominent after 59 days of exposure in weightlessness (the 
Skylab 2 mission) are also evident after only 9 days of exposure in weightlessness. 
that skeletal muscles are susceptible to  functional changes associated with the reduced muscle 
activity in weightlessness. Since all changes showed increased sensitivity, the probable site for 
this effect is the muscle fibers, for the following reason: Previous clinical studies have shown 
that random loss or reduced activity in muscle fibers, as in myopathy, result in higher firing 
frequencies of the muscle, whereas dysfunctions of neural loci result in lower firing frequencies 
(refs. 10-9 t o  10-13). 
Several studies have provided evidence that the electrical activity of muscles increases 
as a function of tension (refs. 10-14 to  10-1 8). Also, previous studies have shown that, after 
a period of immobilization, or, as in myopathy, the EMG amplitudes are depressed when com- 
pared with unaffected muscles (refs. 10-1 3 and 10-19). The results of this study are in agree- 
ment with those findings. 
The greater EMG amplitudes of the gastrocnemius in response to  disuse are not readily 
understood. However, Liberson et  al. (ref. 10-20) have provided indirect evidence that the 
IEMG of the gastrocnemius may show an inverse relationship to  contraction force; that is, 
the highest tensions show the lowest levels of electrogenesis. 
Both upper and lower extremity muscles showed changes in excitability which suggest 
Muscle Electrical Efficiency 
The ratio of IEMG to force appears to  have considerable merit for describing the effi- 
ciency o r  quality of muscle activity under normal gravity conditions. However, the inter- 
pretation of muscle electrical efficiency after disuse is less clear than before disuse. For 
example, the increased postflight electrical efficiency shown in the arm muscles was not 
expected since it was anticipated that all muscles would show a decrease. 
exercise of upper extremities. This possibility, coupled with the short mission duration, 
A possible explanation for this disparity could be the quantity and quality of in-flight 
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the greater use of arms than legs in normal mission operations, and the added possibility that 
the arm muscles are less affected by the absence of gravity than the antigravity muscles, could 
account for postflight enhancement of efficiency. 
Another possible explanation for the observed results, however, is that the increased 
muscle efficiency is an artifact resulting from differences between postflight and preflight 
IEMG levels. Both the biceps and brachioradialis had depressed IEMG levels after flight. 
Thus, smaller postflight EMG amplitudes for comparable preflight and postflight force levels 
would produce smaller IEMG per unit force ratios for postflight data and, therefore, reflect 
a seemingly better efficiency. 
Muscle Fatigability 
That short-term exposure to  weightlessness heightens fatigability in skeletal muscle was 
readily demonstrated in the antigravity muscles by the results of this study. Greater amounts 
of spectral power were observed to develop in the lower frequencies after weightlessness than 
before in response to  the fatigue-inducing stress. These results suggest that the disuse associ- 
ated with whole-body weightlessness temporarily facilitated certain muscle conditions, as 
evidenced by a degree of supersensitivity, which led to  a quickened fatigability and the earlier 
incidence of synchronous discharges and recruitment of higher threshold motor units. 
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1 1. CARDIOVASCULAR EVALUATIONS 
G. Wyckliffe Hoffler,a Arnauld E. Nicogossian,a 
Stuart A. Bergman, Jr.,a and Robert L. Johnsona 
Because of the noxious gas episode during the Apollo-Soyuz Test Project (ASTP) 
command module entry and recovery, most planned postflight evaluations were curtailed, 
altered, or deleted. Preflight baseline data, to  all intents and purposes, were essentially 
normal throughout and will be detailed only in summary form. Definitive data analyses 
and conclusions are not possible after the manner of previous Apollo vehicle recoveries. 
METHOD AND MATERIALS 
On three preflight test dates, 45, 30, and 15 days before lift-off (F - 45, F - 30, and 
F - 15, respFctively), the following cardiovascular evaluations were performed on each 
crewman. 
1. Orthostatic tolerance by lower body negative pressure (LBNP) 
a. Apollo/Skylab stress protocol 
( 1 )  Heart rate 
(2) Systolic blood pressure 
(3) Diastolic blood pressure 
(4) Percentage change in calf volume 
( 5 )  Systolic time intervals 
(6) Vectorcardiograms 
2. Heart size by posterior-anterior chest X-rays (F - 15 only) 
3. Resting (supine) leg volume 
4. Echocardiogram 
1. One LBNP test on the Apollo commander (ACDR) on recovery day (R + 0) 
2. Chest X-rays 
3. Leg volumes 
The only postflight data obtained were 
RESULTS 
Preflight mean (plus or  minus standard deviation) LBNP responses are given in Table 
11-1. Circumstances surrounding each preflight test, time of day, ambient and LBNP 
temperature, time since last meal, and amount of sleep were all nominal and within desired 
a N A S A  Lyndon B. Johnson Space Center. 
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TABLE 1 1-I.-PREFLIGHT LBNP RESPONSES O F A S P  CREWMEN 
[Mean plus or minus standard deviation] 
Measurement Command module Docking module Crew mean Apollo commander pilot pilot 
Heart rate, beats/min 
Resting 
LBNP 
Blood pressure, mm Hg 
Systolic 
Resting 
LBNP 
LBP 
Diastolic 
Resting 
Maximal left calf 
circumference, cm 
LBIW calf volume 
change, percent 
62 f 5 
80f 8 
106 f 7 
102 f 7 
66 f 7 
68 f 5 
35.9 f 0.3 
1.9 f 1.0 
53k 5 
60f  14 
116k 4 
1125 4 
68f  1 
67f  3 
38.8 f 0.2 
2.5 f 0.2 
48 f 5 
51 f 9  
104 
103 f 4  
61 f 5  
63 f 3 
35.7 f 0.5 
3.5 f 0.6 
54f 7 
66 f 21 
109f 6 
1065 6 
655  4 
66f  3 
36.8 f 1.8 
2.6 f 0.8 
a Minus 50 mm Hg. 
limits of experimental control. No results could be considered unusually aberrational; only 
a single episode of presyncope occurred, in the command module pilot (CMP) late in the 
minus 40 mm Hg level of LBNP during the F - 15 test. He had just previously participated 
in vestibular function testing to  the point of symptoms. 
G.m.t. (1 :40 p.m. Hawaii time), approximately 2 hours 20 minutes after splashdown but 
before the major decision to  delete all nondiagnostic and nonclinical testing, are detailed in 
Table 11-11. It should be emphasized that LBNP was stopped at approximately 2 minutes 
into the minus 50 mm Hg level of LBNP because of progressively declining blood pressure. 
The crewman vehemently denied any associated symptomatology. 
mation was obtained from systolic time intervals, vectorcardiograms, or echocardiograms. 
Strictly resting vectorcardiograms were taken on recovery day in conjunction with clinical 
electrocardiograms. All tracings were considered to  be within normal limits. Those of the 
docking module pilot (DMP) showed occasional premature supraventricular beats not unlike 
those observed before flight. 
Mean responses of the ACDR during the only postflight LBNP test, performed at  23:40 
Because LBNP recordings made immediately after flight were deleted, no useful infor- 
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TABLE 1 l-II.-MEAN RESPONSES OFAPOLLO COMMANDER 
DURING POSTFLIGHT LBNP 
[Plus or minus standard deviation] 
Heart rate, beats/min 
Resting 
L B N P ~  
Blood pressure, mm Hg 
Systolic 
Resting 
LBW 
LBW 
Diastolic 
Resting 
70+ 2 
loo+ 5 
104k 7 
74+ 12 
6 2 +  2 
- 
Maximum left calf circumference 
L B w  calf volume change, 
(resting), cm 35.0 
percent t2.0 
aMinus 50 mm Hg. 
Chest X-rays provided heart size determinations by the cardiothoracic (C/T) ratios. 
No notable or consistent findings developed, but these data must be considered in the 
light of significant postflight pulmonary involvement. Cardiothoracic ratio data obtained 
in systole and diastole are summarized in Table 11-111. 
serially after flight according to the applicable detailed test procedure. The report of these 
data is the subject of chapter 12. 
Lower limb volume measurements were obtained during flight by the crewmen and 
CONCLUSIONS 
Apart from the noxious gas event associated with the recovery of the ASTP crewmen 
and their ensuing pulmonary consequences, no findings would lead to  conclusions different 
from that reached with all previous U.S. manned space missions: a modest postflight dec- 
rement in orthostatic tolerance without operational significance was demonstrated. Data 
are mainly documented here for completeness and reference. The in-flight leg volumes 
augment those from the Skylab 4 mission and actually elaborate further on the early in- 
flight period. 
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TABLE 1 1-111.-CARDIOTHORACICRATIO DATA OBTAINED INSYSTOLE AND DIASTOLE 
Preflight, F - 15 Postflight 
(June 28, 1975) R + 0 (July 24, 1975) R +  1 (July 25, 1975) 
Crewmember Dimensions, cm C/T ratio 
Dimensions, 
cm C/T ratio 
Dimensions, 
cm C/T ratio 
Systole 
ACDR 12.8130.3 0.422 12.9130.4 0.424 12.8129.7 0.430 
CMP 13.1132.7 0.400 12.7132.3 0.393 13.7132.2 0.425 
DMP 13.0132.3 0.402 13.0132.1 0.404 12.5131.6 0.395 
Diastole 
- - - - ACDR - - 
CMP 13.2132.8 0.402 12.7132.6 0.389 - - 
DMP 13.6132.3 0.422 14.7132.5 0.452 - - 
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12. IN-FLIGHT LOWER LIMB VOLUME MEASUREMENT 
5000 
(51 
G. Wyckliffe Hoffler,a Stuart A. Bergman, Jr.,a 
and Arnauld E. Nicogossiana 
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Major headward fluid shifts during flight have been seen during multiple observations 
and confirmed in data collected from Apollo and Skylab crews. Dominant among these 
documented data are the preflight and postflight leg volume determinations that were 
calculated from multiple circumferential leg measurements. First measured during flight 
on the Skylab 4 crewmembers, leg volume decrements of a full liter (10 to 15 percent of 
preflight values) occurred as early as mission day 3, when the earliest in-flight measure- 
ments were programed (Figure 12-1). In-flight leg volume measurements were programed 
on Apollo-Soyuz Test Project (ASTP) crewmembers for the following reasons. 
1. T o  substantiate with further data this rather notable finding 
2. To obtain earlier in-flight volume determinations 
3. To document the time course of headward fluid shifts by frequent serial leg 
volume measurements. 
t 5 6000 (6) 
0 Commander 
I 0 Science pilot 
I I Preflight I n -fl ight Postflight 
June I July I I Oct. 1 Nov. 1 Dec. Jan. 1 Feb. I Mar. 
1973 -1- 1974 
Date 
Figure 12-1. Left Leg Volume Measurements of Skylab 4 Crewmen 
aNASA Lyndon B. Johnson Space Center. 
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METHOD AND MATERIALS 
A simple jig template with an accompanying flexible measuring tape similar to the 
Skylab 4 limb volume measuring kit was provided (Figure 12-2). The single difference from 
the Skylab 4 kit design was reduction of the number of circumferential position measure- 
ments from 25 t o  12, chiefly as a concession to crew time constraints. To preserve the 1- to 
2-percent resolution of the method, these 12 template positions were optimized by preflight 
crew adaptations. 
During the period from 45 days before lift-off ( F  - 45) t o  1 day before lift-off ( F  - l) ,  
five independent determinations of the left leg volume were made. Crewmembers were 
instructed and trained in the procedure and actually conducted the F - 1 measurements on 
themselves to ensure adequate familiarization for their seven in-flight measurement sessions. 
Right leg measurements were obtained three times before flight and once on recovery day 
(R + 0) by medical team personnel. Because of circumstances associated with the toxic 
nitrogen tetroxide gas event during the recovery period, leg volumes were not obtained be- 
yond the fourth postflight day (R + 4). 
Figure 12-2. The ASTP In-Flight Leg Volume Measuring Kit Including 
Template, Tape Measure, and Stowage Pouch 
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RESULTS 
In chronological sequence, all leg volume determinations are tabulated from all three 
flight phases (Table 12-1). Decreasing leg size as the launch period approached is in accord- 
ance with preflight findings from previous flight crews. Mean preflight volumes with stan- 
dard deviations and their 95-percent confidence ranges are included. 
ground elapsed time (GET) on the command module pilot (CMP). This value fell only 260 
cm3 (0.26 liter) below his F - 1 volume but was still a statistically significant (P < 0.05) 
volume reduction. By 32:OO GET, all three crewmen had evidenced substantially greater 
in-flight decrements (5 to 10 percent). All four of these values were observed earlier during 
flight than in the previous earliest in-flight leg volume measurements obtained on Skylab 4 
mission day 3. Subsequent determinations showed moderate variability with a definite 
continuing downward trend, except for the last value at 205:OO GET on the CMP. Most 
variations were parallel in all three crewmen despite the fact that different crewmembers 
contributed to measurement variance. All in-flight volumes dropped below the lower 95- 
percent confidence limit established by preflight volumes determined over a 45-day period. 
Earliest postflight determinations were taken between 1.5 and 2 hours after splash- 
down, about as early as any such data have been acquired on U.S. space crews. Even so, 
leg volumes on all three crewmen had already increased well above their last in-flight values. 
Second measurements on recovery day, some 2 to 5 hours after splashdown, evidenced even 
greater leg volumes, in accord with the reversing effects of readaption in normal gravity. 
Leg volumes taken on July 25, 1975 (day R+ l) ,  were achieved before arising that morning 
and show clearly the established diurnal pattern of minimal volume at the end of the sleep 
period in a horizontal position. The last postflight values, taken on July 28, 1975 (day R + 4), 
exhibit distinctly increasing trends toward preflight values. 
The earliest in-flight determination (Figure 12-3) was obtained at approximately 06:OO 
CONCLUSIONS 
When considered in conjunction with the earlier Skylab 4 in-flight data on mission days 
3, 5, and 8, the comparable flight period, several of the oscillatory variations observed in 
ASTP flight crewmembers may be judged to be actual physiologic damping responses. In 
any case, in-flight data from the Skylab 4 and ASTP missions are quite complementary and 
consis tent . 
With a single datum for inference, it appears that the major shift of fluid volume from 
the legs does not occur in the first few hours of orbital exposure. The course seems more 
likely to assume an exponential form with maximal rate of decrement within the first 24 
hours. A distant plateau is evident by 3 to  5 days with little significant additional decrease 
occurring after the first week in weightlessness. These fluid volume shifts coincide with the 
occurrence of major crew symptomatology and the plateau with relative adaptive stability. 
More elaborate studies for clarification of the events observed here must await the Space 
Shuttle era. 
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Figure 12-3. Left Leg Volume Measurements of ASTP U.S. Crewmen 
AC KNO WLE DCMENTS 
The engineering and production of the in-flight limb volume measuring kit was assured 
by R. Nolte. The ASTP crewmen cooperated magnificently in learning the technique and 
providing all in-flight data. This detailed test objective doubled the existing data on in-flight 
leg volume changes and is a credit to  the many who have pioneered simple methods for at- 
taining important achievements. 
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13. MEDICAL MICROBIOLOGICAL ANALYSIS OF 
U.S. CREWMEMBERS 
Gerald R. Taylora 
On early Apollo missions before strict protective measures were instituted, in-flight 
infections were not unusual (ref. 13-1). In-flight illness of microbial origin was, however, 
completely absent from the Apollo 14 to 17 missions (ref. 13-2). There is no doubt that 
implementation of extensive preventive measures (ref. 13-3) following the clinically sig- 
nificant Apollo 13 mission was a contributing factor. Preflight monitoring of pathogenic 
and potentially pathogenic microbial species identified certain potential problems so that 
appropriate prophylaxis or treatment could be administered before the flight or could be 
provided during flight. This procedure was highly effective and was recommended for all 
future U.S. manned space flights (ref. 13-2). Although similar analyses conducted during 
the three Skylab flights demonstrated the occurrence of several in-flight disease events 
and evidence of gross contamination of the orbital workshop, such events were not shown 
t o  be limiting hazards for long-duration space flights.' 
The Apollo-Soyuz Test Project (ASTP) was a unique space flight in which two teams 
of crewmembers from different geographical areas joined their respective spacecraft in 
space; this mission presented an unusual opportunity for microbial cross-contamination. 
Accordingly, it was necessary t o  identify and trace all microorganisms of potential medical 
importance present in this population. This report covers such an analysis of the three 
flight and three backup Apollo astronauts that was conducted as part of the Microbial 
Exchange Experiment. A report of the joint experiment, including analyses of data from 
the two flight and two backup U.S.S.R.cosmonauts, is presented in the ASTP Preliminary 
Science Report (ref. 13-4). 
METHOD AND MATERIALS 
Baseline Microbial Specimen Collection 
Nine sets of specimens were collected from the three prime Apollo crewmembers as 
follows: 45, 30, 15, and 7 days before lift-off (days F - 45, F - 30, F - 15, and F - 7,  re- 
spectively) and on launch day (F - o); once during flight; and on recovery day (R + 0) and 
1 5 and 30 days after recovery (R + 1 5 and R + 30, respectively). Additionally, six sets of 
control specimens were collected from the three backup Apollo crewmembers before flight 
on days F - 45, F - 30, F - 15, F - 7, and F - 0, and immediately after the flight. 
aNASA Lyndon B. Johnson Space Center. 
'Gerald R. Taylor, et al.: Skylab Environmental and Crew Microbiology Studies. Biomedical Results from Skylab, 
NASA SP-377, in press. 
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During each preflight and postflight sample period, microbial specimens were collected 
from 10 sampling sites on each crewmember (Table 13-1). Calcium alginate swabs wetted in 
0.3-mM phosphate buffer were used to  sample each of the seven body surface areas. This 
swab technique was chosen as the only collection method compatible with the flight program. 
Although it is recognized that subsurface microbes may be overlooked by this method, pro- 
cedures for sampling subsurface areas were not acceptable. Dry calcium alginate swabs were 
used to sample the surfaces of the tonsils and the posterior pharyngeal vault before collection 
of the gargle specimen. For this latter sample, the subject gargled with 0.3-mM phosphate 
buffer followed by a repeated rinse of the teeth with the same solution. The swabs were 
placed in 5 cm3 of 0.3-mM phosphate buffer for transport to  the laboratory. Analysis of 
all samples was initiated within 1 hour of specimen collection. 
TABLE 13-I.-CREW SAMPLE COLLEC7TONSITES 
Sample Sample 
no. designation Area sampled 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Hair 
Ears 
Neck 
Nares 
Throat swab 
Hands 
Axillae 
Groin 
Toes 
Gargle 
20-cm2 area of hair (and scalp) on top of head 
Right and left external auditory canals with 2 
20-cm2 area below hairline at base of neck 
Internal area of both nostrils 
Surfaces of tonsils and posterior pharyngeal vault 
20-cm2 area on right and left palms 
20-cm2 area below hair on each side 
5-cm strip from rear to front on right and left 
revolutions of each swab in each ear canal 
inguinal area between legs 
Area between the 2 smallest toes of each foot 
10 cm3 of phosphate buffer used as gargle and 
washed through oral cavity 3 times 
In- Flight Microbial Specimen Collection 
In addition t o  the baseline samples described previously, in-flight samples were obtained 
from all five flight crewmembers and both spacecraft between 77:40 and 78:30 Soyuz ground 
elapsed time. The in-flight samples were made from swabs of the first six areas listed in 
Table 13-1. For this set of samples, a specially developed sample collection device was em- 
ployed (Figure 13-1). This device consisted of a cotton-tipped Teflon swab on a capillary 
70  
MEDICAL MICROBIOLOGICAL ANALYSIS OF U.S. CREWMEMBERS 
- - - - -___ Swab cover.- _ _ _  - 
Capillary lube--_ 
Swab case- 
----___. 
----____ 
Airspace- _ _  _ _  - - -__  
Cotton swab - -_____ - - -__ 
. .  . 
. . .  . .  . . .  
* 
11 rnrn 
Figure 13-1. In-Flight Microbial Sample Collection Device 
tube which contained conservation fluid to  keep the microorganisms alive. Each swab was 
housed within an airtight case t o  prevent desiccation. Groups of swabs were organized in 
Beta-cloth retaining bags, an example of which is shown in Figure 13-2, 
The contents of each swab and gargle sample were serially diluted under aseptic condi- 
tions and subsequently inoculated onto the surface of the nutrient media (Table 13-11]. The 
variety of media, the number of plates inoculated, and the dilution range were selected on 
the basis of what was required to isolate and quantitate the autoflora components present 
in each sample area. Sabouraud's dextrose agar (SAB) plates were incubated at 303 K (30" C) 
for 5 days. Cornmeal, maltextract, yeast extract (CMMY) agar plates were incubated at 
298 K (25" C) for 7 days, and all others were incubated at 31 0 K (37" C) for 48 hours. 
Following incubation under the appropriate conditions, all resulting colonies were 
categorized and counted on every culture plate. Subsequently, one sample of each mor- 
phologically different colony type was transferred from each dilution series t o  the appro- 
priate nutrient media and was stained according to  the method of Gram. Species were 
identified as previously outlined (refs. 13-5 and 13-6). 
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Figure 13-2. Beta-Cloth Sample Collection Kit Used to 
Sample Crewmembers in Apollo Spacecraft. 
Open Kit Shows Sample Collection Devices in Place 
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TABLE 13-II.-ISOLAl7ON MEDIA USED 
Sample type Number of 
plates Media hlution range 
Back of neck 
Hair 
Hands 
Axillae 
Auditory canals 
Gargle (natural) 
Gargle (centrifuge) 
Nostrils 
Toe webs 
Groin 
Throat swab 
Blooda 
Manni tolC 
C M M Y ~  
S A B ~  
Blood 
Mannitol 
CMMY 
Chocg 
CMMY 
SAB 
Blood 
Mannitol 
CMMY 
SAB 
Choc 
Blood 
Mannitol 
CMMY 
SAB 
Blood 
Mannitol 
CMMY 
SAB 
Choc 
Rogosa 
Rogosa f 
2 
3 
4 
5 
2 
3 
4 
3 
3 
4 
5 
2 
3 
4 
5 
3 
2 
3 
4 
5 
2 
3 
4 
5 
3 
3 
b10O to 104 
loo to 10' 
100 
1 00 
loo to lo5 
IO0 to 10' 
100 to 102 
loo to lo3 
ioo to io5 
1 oo 
1 oo 
ioo to io4 
loo to lo3 
1 oo 
1 oo 
loo to 10' 
ioo to io5 
100 to 10' 
100 
1 oo 
ioo to io5 
100 to 10' 
100 to 102 
1 oo 
ioo to lo5  
loo to lo3 
a Blood = blood agar. e SAB = Sabouraud's dextrose agar. 
3 IOo = sample in 5 cm of phosphate buffer. 
Mannitol = mannitol salts agar. 
Rogosa = Rogosa agar. 
Choc = chocolate bacitracin agar. 
d CMMY = cornmeal, maltextract, yeast- 
extract agar. 
73 
THE APOLLO-SOWZ TEST PROJECT MEDICAL REPORT 
RESULTS 
Enteric Microorganisms 
A number of different microbes that occur normally in the intestinal tract or that are 
associated with intestinal infection are placed in the enteric group of bacilli. The normally 
occurring members of this group are generally considered to  be of potential medical im- 
portance when they are recovered repeatedly, or  in large numbers, from sites other than 
the lower digestive tract. The following members of this group were recovered from areas 
on the ASTP crewmembers other than the lower digestive tract. An outline of the total 
recovery pattern for the Apollo crewmembers is presented in Tables 13-111 to  13-VI. 
Escherichia coli species. - The presence of Escherichia coli species is generally accepted as 
the most reliable evidence of fecal contamination. Outside the intestinal tract, under 
certain conditions, it often produces diseases such as the following: urinary tract infec- 
tions (cystitis and pyelitis), peritonitis, gallbladder infection, wound infection, septicemia, 
and enteritis. This species was repeatedly recovered from the groin of the flight command 
module pilot (CMP) and occasionally from the upper respiratory tract of the other two 
flight crewmembers. In all cases, neither the recovery pattern nor the quantitation indi- 
cated medical significance. 
Enterobacter aerogenes species.- The microorganism Enterobacter aerogenes often occurs 
in the large intestine of man, although the number present is considerably smaller than 
that of Escherichia coli. Its pathogenic significance is similar t o  that of Escherichia coli. 
As indicated in Tables 13-111 and 13-IV, this species was always carried in the nasal and 
buccal cavities of the flight CMP and docking module pilot (DMP) and was frequently 
isolated from the backup Apollo commander (ACDR) and DMP. Although this is an 
uncommon occurrence, it should be noted that this species was not shown to  spread to 
the flight ACDR or to more sites on the carriers during the flight. Also, there were no 
postflight increases in quantitation. Although carried by two flight crewmembers, this 
potential pathogen apparently was unaffected by the conditions of space flight. 
Proteus rnirabilis species.- Species of the genus Proteus may cause infection of the urinary 
tract and abscesses. Additionally, these microbes have been incriminated in outbreaks of 
enteric infection, particularly gastroenteritis. More often, they are secondary invaders in 
infections of the middle ear, the mastoid, meninges, wounds, and the urinary tract. The 
most frequent species of this genus found in human clinical material, P. rnirabilis was 
carried in low numbers in the nasal passage of the flight ACDR throughout the monitor- 
ing period. As in the case of E. aerogenes described previously, this unusual mission 
provided a good model system for analyzing the response of Gram-negative rods t o  space- 
flight conditions. The ASTP mission had no effect on the qualitative or quantitative 
presence of this microorganism. 
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Other Gram-Negative Rods 
Nor?enterir Gram-negative rods discmsed include species of the Moraxella genus, 
Acinetobacter calcoaceticus organisms, and four species of Haemophilus. 
Moraxella species.-Species of the genus Moraxella are parasites found in the mucous 
membranes of man and are frequently involved in pathogenic activity such as conjunctivitis. 
Although carried in the oral cavity of the flight DMP for 45 days before the flight, no dis- 
cernible microbial alteration was demonstrated following the mission. 
Acinetobacter calcoaceticus species.-Acinetobacter calcoaceticus (synonym: Mima poly- 
morpha) is a species of minor potential medical importance. Isolated infrequently from 
multiple sites on the flight CMP, it did not contribute significantly t o  the load of Gram- 
negative rods recovered from ASTP flight crewmembers. 
Haemophilus species.-Four species of Haemophilus were isolated from the oral cavity of 
each ASTP astronaut (Tables 13-V and 13-VI). Although each of these species is t o  some 
degree a common inhabitant of the human mouth, each is a strict parasite, requiring certain 
growth factors present in blood. The potential medical importance of each is noted as 
follows. 
Haemophilus influenzae is found in lesions and in the upper respiratory tract of car- 
riers. It may be either a primary or a secondary invader. As a primary incitant of disease, 
it is responsible for meningitis, septicemia, conjunctivitis, and upper respiratory tract infec- 
tions. It is commonly a secondary invader in cases of influenza and pertussis. This species 
was isolated from each of the crewmembers before flight in quantitations ranging from 
10 000 to 600 000 viable cells/cm3 of gargle. The postflight loss from two crewmembers 
and the quantitative reduction in contamination of the ACDR is contraindicative of a 
space-flight-mediated increase in infective potential. 
Haemophilus haemolyticus and H. parahaemolyticus are often associated with acute 
pharyngitis when present in high numbers. As with the H. influenzae, the overall quanti- 
tation and incidence decreased following the ASTP flight. 
Haemophilus parainfluenzae is the most benign of the four species recovered and is 
used largely as a marker organism because of its almost ubiquitous appearance. 
Candida albicans 
Candida albicans (ref. 13-7), a well-recognized component of the indigenous autoflora 
of man, has been recovered from astronaut specimens collected in association with each 
of the Apollo and Skylab missions (refs. 13-2 and 13-8).* Because C. albicans has 
been identified as the causative agent for serious oral cavity diseases (refs. 13-7 and 13-9), 
the presence of this microorganism in the mouth of astronauts was carefully monitored. As 
previously reported (ref. 13-9 ,  C. albicans was recovered from crewmembers following the 
Apollo 14 and 15 missions, whereas other fungal species, present before flight, were absent 
from samples obtained immediately after recovery. Analysis of the ASTP data presented in 
Table 13-VI1 indicates an in-flight transfer of this species to the ACDR. No such transfer occurred 
'Ibid. 
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TABLE 13-V.-RECOVER Y OF GRAM-NEGATIVE RODS FROM 
ASTP APOLLO FLIGHT CREWMEMBERS 
[Genus Haemophilusl 
Crew- Species of 
Quantity of bacteria, log,, colony-forming units/crn 3 
of  gargle or swab diluent, for day - 
member Hae mophi I us 
F - 4 5  F - 3 0  F - 1 5  F - 5  F - 0  R t O  R + 1 5  R + 3 0  
ACDR 
CMP 
DMP 
ACDR 
CMP 
DMP 
H. haemolyticus 0 
H. influenzae 0 
H. parahaemolyticus 0 
H. parainfluenzae 4.50 
H. haemolyticus 5.60 
H. influenzae 5.77 
H. parahaemolyticus 0 
H. parai nfluenzae 5.69 
H. haemolvticus 0 
H. influenzae 0 
H. parahaemolyticus 0 
H. para i nf I uenzae 5.41 
H. haemolyticus 0 
H. influenzae 0 
H. Darahaemolvticus 0 
H. parainfluenzae 5.54 
H. haemolyticus 0 
H. influenzae 5.69 
H. Darahaemolvticus 0 
H. parainfluenzae 6.23 
H. haemolyticus 0 
H. influenzae 0 
H. parahaemolyticus 4.69 
H. uarainfluenzae 5.44 
0 
0 
0 
5.04 
5.47 
0 
0 
6.04 
0 
0 
0 
5.23 
4.47 
4.90 
0 
5.36 
0 
0 
4.00 
5.14 
4.47 
0 
0 
4.84 
Throat swab 
Gargle 
0 
4.90 
0 
5.99 
6.30 
0 
0 
7.08 
0 
0 
0 
6.04 
6.49 
5.77 
0 
6.77 
0 
0 
6.30 
7.20 
5.77 
0 
0 
6.43 
0 
0 
0 
5.1 7 
0 
0 
5.90 
5.90 
0 
0 
0 
6.46 
0 
0 
0 
6.53 
6.90 
0 
7.1 1 
7.39 
0 
0 
5.30 
6.80 
0 
0 
0 
5.20 
0 
0 
0 
5.36 
0 
4.00 
0 
5.45 
0 
0 
0 
6.53 
0 
0 
0 
6.48 
0 
0 
0 
6.28 
0 
3.34 
0 
3.49 
3.30 
0 
0 
3.84 
0 
0 
0 
4.77 
5.30 
0 
5 .oo 
5.95 
0 
0 
0 
5.15 
0 
0 
5.30 
5.52 
0 
0 
0 
4.62 
0 
0 
0 
5.87 
0 
0 
5.1 1 
4.90 
0 
0 
0 
5.08 
0 
0 
0 
6.48 
5.78 
0 
5 .oo 
6.1 5 
0 
0 
0 
2.18 
0 
0 
0 
5.49 
0 
0 
0 
4.00 
0 
1.48 
0 
4.18 
0 
0 
0 
7.00 
0 
0 
0 
5.46 
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TABLE 13-Vl-RECOVERY OFGRAM-NEGATIVERODS FROM 
ASTP APOLLO BACKUP CREWMEMBERS 
[Genus Haemophilus] -- 
Quantity of bacteria, log,, colony-forming units/cm 3 
Crew- Species of of gargle or swab diluent, for day - 
member Haemophilus 
F - 4 5  F - 3 0  F - 1 5  F - 5  F - 0  R + O  
ACDR 
CMP 
DMP 
ACDR 
CMP 
DMP 
H. haemolyticus 
H. influenzae 
H. parahaemolyticus 
H. parai nf I uenzae 
H. haemolyticus 
H. influenzae 
H. para hae mol yticus 
H. parainfluenzae 
H. haemolvticus 
H. influenzae 
H. parahaemolyticus 
H. parainfluenzae 
H. haemolyticus 
H. influenzae 
H. parahaemolyticus 
H. parainfluenzae 
H. haemolvticus 
H. influenzae 
H. parahaemolyticus 
H. Darainfluenzae 
H. haemolyticus 
H. influenzae 
H. Darahaemolvticus 
H. parainfluenzae 
0 
0 
4.30 
5.32 
0 
0 
0 
4.34 
0 
0 
0 
2.44 
5.47 
0 
0 
5.95 
0 
0 
0 
4.70 
0 
3.00 
4.25 
0 
Throat swab 
4.60 
0 
0 
4.95 
0 
0 
0 
2.30 
0 
4.00 
0 
5.20 
Gargle 
0 
0 
0 
6.54 
0 
0 
0 
0 
0 
0 
0 
6.73 
0 
0 
4.1 1 
7.95 
0 
0 
4.65 
3.95 
0 
0 
0 
4.41 
0 
0 
0 
6.60 
0 
0 
6.00 
6.43 
0 
0 
0 
7.43 
0 
0 
0 
5.81 
0 
0 
4.65 
3.60 
5.04 
3.00 
0 
4.69 
0 
0 
0 
0 
0 
0 
6.77 
6.36 
0 
0 
0 
7.43 
0 
0 
0 
6.05 
0 
0 
4.57 
4.48 
0 
3 .OO 
0 
4.04 
0 
0 
0 
6.49 
0 
0 
0 
5.86 
0 
0 
4.00 
5.81 
0 
0 
0 
5.38 
0 
0 
0 
4.57 
0 
0 
0 
4.1 5 
5.00 
0 
0 
6.36 
0 
0 
5.30 
6.4 1 
0 
0 
4.30 
5 .oo 
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TABLE 13-WI.-RECOVER Y O F  Candida albicans FROM THE 
MOUTHS OF APOLLO CREWMEMBERS 
Days before or during flight Days after flight 
L'l. W.11l.11I"b.l 
F - 4 5  F - 3 0  F - 1 5  F - 5  F - 0  F + 5  R + O  R + 1 5  R + 3 0  
Flight 
ACDR Aa A A A 
CMP P P P P 
DMP A P P P 
Backup 
ACDR A A A A 
CMP P P P P 
DMP A A A A 
A A Pb A A 
P P P P P 
P A P P P 
A NSC A NS NS 
P NS P NS NS 
A NS A NS NS 
aAbsence of C. albicans. 
bResence of C. albicans. 
'No sample taken. 
with the backup controls, although C. albicans was camed in the oral cavity of the backup 
CMP. All of  these events demonstrate the importance of this species in space flight. It 
could become even more important during in-flight use o f  antibiotics since this could pro- 
vide the opportunity for a loss of competing bacterial species and eventual overgrowth with 
C. albicans (refs. 13-9 to  13-1 1). 
Staphylococcus aureus 
Although Staphylococcus aureus microorganisms are not uncommon skin and nasal 
contaminants, all strains are potential pathogens. They have been shown t o  be the causative 
agent of  a wide range of  infections and intoxications including abscesses, meningitis, furun- 
culosis, pyemia, osteomyelitis, suppuration of  wounds, and food poisoning (ref. 13-1 2). 
Several space-flight simulation studies have indicated increases in the toxicogenic activity, 
virulence, or  pathogenicity of this species with stressful confinement of the human host 
(refs. 13-13 to 13-15). If these events were t o  be duplicated during space flight, the result- 
ing lesions could be especially important because of their interference with close-contact 
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surfaces, such as the tight-fitting and abrasive pressure suits. Accordingly, the presence and 
the activity of this species were monitored before and after each of the recent U.S. space 
in-flight cross-contaminations with S. aureus (ref. 1 3-2).3 
flights is presented in Table 13-VIII. The ASTP flight DMP had not been assigned to a pre- 
vious space-flight mission; therefore, such data were nonapplicable. Strains of s. aureus 
were recovered from all the other five ASTP crewmembers in connection with at least one 
previous space-flight mission. 
in Table 13-IX. These strains are expressed as numbered bacteriophage types. The data 
show that each of the flight and backup crewmembers carried a different strain of S. aureus. 
One type (52, 52A, 80, 81) was carried by the DMP and transferred t o  the ACDR during 
flight. Apparently, colonization did not ensue because this strain was not again recovered 
from the flight ACDR. 
A postflight increase in the incidence of S. aureus isolation has been reported pre- 
viously (ref. 1 3-2).3 In the ASTP mission, this postflight increase did not occur among 
the astronaut population. Contrary to some previous missions? no disease events resulted 
from the ubiquitous presence of S. aureus before and during the flight. 
riglitso n u;lca - c--- l l U l l l  thn C l l b  Ai;o!!o 13, 14, m d  15 missicx?s ax!  frm? the Cky!2h missinns cnnfirrr! 
The recovery of S. aureus from ASTP crewmembers in connection with previous space 
The recovery of strains of S. aureus during the ASTP monitoring period is presented 
Total Load of Potential Pathogens 
Several authors have warned that returning space travelers may experience a “microbial 
shock” and may respond negatively t o  renewed contact with potentially pathogenic micro- 
organisms which are absent in the space-flight environment (refs. 13-1 and 13-1 6 t o  13- 18). 
These warnings were based on the assumption that contact with potential pathogens during 
space flight would be very limited and would thus result in a reduction of immunocompetence. 
However, there was no demonstrable decrease in the incidence of medically important micro- 
organisms recovered from the astronauts on recovery day. This finding supports earlier re- 
ported results (refs. 13-6, and 13- 19). Therefore, any reduction in total immunocompetence 
during the ASTP mission could not have been in response t o  decreased contact with medically 
important components of the resident microflora. 
CONCLUSION 
This analysis of medically important microorganisms was conducted as a part of the 
ASTP Microbial Exchange experiment. Although several potential pathogens were recovered 
from each of the flight and backup crewmembers before and after flight, no disease events 
were reported. Candida albicans and staphylococcus aureus (52, 52A, 80, 81) were shown 
to have been transferred from one crewmember to another during flight. No other medically 
significant changes in the microbial population were observed. 
31bid. 
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TABLE 13-VIII.-Staphylococcus aureus RECOVERY FOR US.  
CRE WMEMBERS COLLECTED BEFORE ASTP FLIGHT 
Crewmember Flight Sampling day Sample area Phage type 
ACDR Apollo IO 
CMP Apollo 15 
Skylab 3 
Skylab 4 
DMP Clinic 
ACDR ApoUo 12 
Skylab 3 
CMP Apollo 14 
D W  Skylab 3 
Fhght ASTP crew 
F - 3 0  Hands 
F .30 Scalp 
Nose 
F - 5  Nose 
Mouth 
F - 30 Groin 
Nose 
F - I 4  Groin 
F - 5  Mouth 
Nose 
F - 3 0  Groin 
Nose 
F - 1 4  Nose, Groin 
Mouth 
F - 5  Ear, groin 
Nose 
Mouth, scalp 
- Mouth 
Backup ASTP crew 
F .30 
F.14  
F . 0  
R t O  
F .45 
F - 1 4  
F - S  
F - 0  
R t O  
R t 8  
R t  15 
F .  14 
F - 4 5  
F -  14 
F - 5  
R t O  
R t  8 
R t  18 
Scalp, ean, axilla, 
Nose 
Toes, nose 
Nose 
Nose, mouth 
Scalp, navel, nose, 
Nose 
Nose 
Hands 
Nose 
Nose, hands, navel 
Groin 
NW. axilla, hands 
Navel 
Nose. hands 
hands, nose, groin 
groin 
kdP 
SfdP 
Groin 
Nose 
Nose 
Hands 
Nose 
Mouth, scalp, feces 
Hands 
NOK 
Mouth 
NOX 
Mouth 
N A ~  
N T ~  
85 
85 
NT 
NT 
75/85 
NT 
75/95 
NT 
NT 
75/85 
NT 
75/85 
NT 
29/75 
29/47/75 
83A 
NA 
NA 
NA 
NA 
3A 
3A 
3A 
3A 
3A 
3N3C 
3N3C 
3A 
3A/3C 
3A 
3c 
6/47/53/54/77/ 
79/80/81 
29/79 
29/79/80 
29/53/54/79/80 
29/53/54/79/80 
29/79 
NT 
29/79 
3A 
29/53/54/79/80 
29/53/79/80 
29/79 
29/53/79/80 
'Not applicable ( l y p h  not done). 
bNonlypblc. 
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14. BIOCHEMISTRY AND ENDOCRINOLOGY RESULTS 
Carolyn S. Leacha 
The biochemistry and endocrinology studies were conducted to  provide data which, 
when integrated with information from other medical disciplines, permit an objective as- 
sessment of the individual crewman's health. Additionally, the data collected during the 
preflight phase of the Apollo-Soyuz Test Project (ASTP) mission provided baseline informa- 
tion for the medical team in detecting and identifying postflight physiological changes 
which may have resulted from exposure to  the space-flight environment. The results of 
these tests not only helped in the diagnosis of abnormalities but also provided rationale 
for accurate remedial procedures.' 
METHODS 
Analyses were performed on venous blood three times before the mission: 30, 15, 
and 5 days before lift-off (days F-30, F-15, and F-5, respectively). Postflight blood was 
drawn as soon as possible (ASAP) after recovery (day R + 0) and 28 days later (day R + 28). 
All preflight blood samples were obtained fasting. On the same day that blood was drawn, 
24hour  urine samples were collected from each crewman. 
During the preflight and postflight periods, the crew consumed the diet of their choos- 
ing but followed the provided ASTP diet during flight. Fluids were available when desired. 
Analyses on the blood (plasma or serum) samples included: glucose (Glu), cholesterol 
(Chol), serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transam- 
inase (SGPT), blood urea nitrogen (BUN), uric acid, alkaline phosphatase (Alk Phos), 
calcium (Ca), magnesium (Mg), inorganic phosphate (PO,), bilirubin total (Bili T), creatinine 
(Creat), creatine phosphokinase (CPK), lactic dehydrogenase (LDH), osmolality (Osmol), 
sodium (Na), potassium (K), chloride (C 1 ), triglycerides (Trigly), adrenocorticotrophic 
hormone (ACTH), angiotensin I (ANGIO I ) ,  aldosterone (ALDO), and cortisol. The 24- 
hour urine samples were analyzed for: specific gravity (sp. gr.), Osmol, Na, K, C l ,  Ca, Mg, 
inorganic phosphate, uric acid, Creat, ALDO, antidiuretic hormone (ADH), cortisol, 
epinephrine (Epi), norepinephrine (Nor), and amino acids. 
pilot (DMP) and the command module pilot (CMP), 15 days before the flight and immedi- 
ately after flight. These compartments included plasma volume (iodine-1 25 ( 125 I)), total 
body water (tritium (3H)) ,  extracellular fluid (sulfur-35 (35 S)), and total body exchange- 
able potassium (42 K). The analytical procedures used have been described previously.2 
Body compartments were determined on two of the crewmen, the docking module 
aNASA Lyndon B. Johnson Space Center. 
'Life Sciences Directorate, Lyndon B. Johnson Space Center: Medical Requirements, Apollo-Soyuz Test Project. 
'Lyndon B. Johnson Space Center: Skylab Biomedical Analytical Laboratory Procedure. JSC-07795, 1973. 
JSC-09242, Oct. 1974. 
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The data are given for each crewman. Where possible, the preflight mean (PM) and 
standard deviation (SD) are shown after the preflight values, and each postflight value 
obtained is given. Because of the concern for crew health, the originally approved schedule 
was not followed after flight. Blood samples for complete analyses were drawn on days 
R + 0 and R + 28. Limited plasma was available from the immunology studies on days 
R + 1,  R + 8, and R + 13. These samples were analyzed for cortisol and ALDO. 
RESULTS 
Blood (plasma or serum) biochemistry findings are shown in Tables 14-1 and 14-11. 
The results show postflight decreases below preflight values for glucose in the CMP and 
the DMP, for cholesterol in the Apollo commander (ACDR) and the CMP, and for uric 
acid in the ACDR and the DMP. Increases above preflight values are observed in SCOT, 
SGPT, BUN, Alk Phos, Creat, LDH, and ANGIO I. The LDH isoenzyme values are given 
in Table 14-111. These results show nearly equal distribution of the total LDH increase 
through all five bands on R + 0. By day R +  28, the elevation was shifted more toward LDH 
isoenzyme 1 for the ACDR and the CMP. The DMP’s results were still more generally 
elevated in bands 2, 4, and 5 .  
decrease in Na, K, and C1 in all three crewmen. Increases after flight are seen in hydrogen 
ion (H+), cortisol, and ALDO. 
ticipated in these tests. Postflight decreases were measured in plasma volume, total body 
water, extracellular fluid, and total body exchangeable K. 
Immediately upon entry, the three astronauts excreted significantly higher amounts 
of total hydroxylysine (p < 0.05) and total hydroxylysine glycoside (Tables 14-VI1 and 
14-VIII). The latter increase was caused entirely by galactosyl hydroxylysine in the DMP 
( p  < 0.01), and t o  both glycosides in the CMP (p < 0.01). Consequently, the ratio glucosyl- 
galactosyl hydroxylysine (GLU-GAL)/galactosyl hydroxylysine (GAL), normally having an 
average value of 1.50, decreased in the ACDR but increased in the other two crewmembers. 
The changes in the urinary excretion of free hydroxylysine were significant only in one 
crewmember (DMP, p < 0.05). All the increased values had returned to  normal 28 days 
after entry. 
The 24-hour urine results are given in Tables 14-IV and 14-V. There is a postflight 
The body compartment results are given in Table 14-VI. Only two crewmen par- 
DISCUSSION 
The test results of U.S. crewmen on the 9-day ASTP flight were similar t o  the findings 
on recovery of previous space-flight crews from missions of comparable duration (ref. 14-1). 
Weight loss has been a nearly universal finding after exposure to  weightlessness. The weight 
loss on this flight was variable; the ACDR actually gaining 0.5 kg (1  lb). The postflight urine 
results and the body compartment results indicate that body fluids and electrolytes were 
decreased on return t o  normal gravity and that a process of conservation by the body had 
been initiated at R + 0. This process is shown in particular by the ANGIO I and ALDO results. 
88 
BIOCHEMISTRY AND ENDOCRINOLOGY RESULTS 
TABLE 1QI.-PLASMA ENDOCRINE RESULTS 
eT4, fTSH, BHGH, D B H ~  dT3, activity, percent Sample ANGlO I, Cortisol, ALDO, Insulin, 
day mcrg/ml/h rg/100ml pg/ml arU/rnI I UC uptake r d 1 0 0  ml d / m l  ng/ml 
F - 30 
F - 1 5  
F - 5  
PM f Sd 
R +  0 
R +  1 
R +  8 
R +  13 
R +  28 
F -  30 
F -  15 
F - 5  
PMfSD 
R +  0 
R +  1 
R +  8 
R +  13 
R +  28 
0.78 13.4 282 11 
1.95 15.2 91 15 
1.58 15.5 432 12 
1.44f0.6 14.7f1.1 2 6 8 f 1 7 1  1 3 f 2  
2.82 15.0 257 61 
- 12.7 368 - 
- 10.1 200 - 
- 19.5 368 - 
.92 15.5 202 15 
ACDR 
29.9 
23.3 
28.1 
27 f 3.4 
26.2 
27.0 
- 
CM P 
1.19 13.0 21 1 8 41.8 
.31 16.3 209 10 34.6 
.40 10.1 215 10 34.6 
.63 f 0.48 13.1 f 3.1 212 f 3 9 f 1 37.0 f4.2 
.82 21.0 287 9 39.1 
- 11.4 368 - 34.7 
- 5.5 206 - - 
- 14.7 309 - - 
.52 10.7 403 15 - 
DM P 
31.5 9.6 2.8 1.2 
- 8.8 2.7 1.2 
33.5 6.0 -h - 
32.5f1.4 8 .1f1 .9  2.75f0.1 1 .2fO 
- - 2.7 0.9 
32.7 10.6 1.6 1.2 
36.5 12.6 1.6 - 
- 10.0 1.3 1 .5 
34.6f2.7 1 1 . l f 1 . 4  1 .5f0 .2  1 .4f0 .2  
- - 1.5 1.8 
- - - - 
- - - - 
30.0 5.6 1.7 1.2 
F -  30 0.21 16.3 157 8 18.8 34.6 7.3 1.6 1 .5 
F - 1 5  .37 11.0 191 8 13.4 36.5 6.1 1.9 1.5 
F -  5 .13 18.5 255 12 15.4 34.2 5.6 2.1 1 .5 
PMfSD .24f0 .12  15 .3f3 .9  2 0 1 f 5 0  9 f 2  15.9f2.7 35.1f1.2 6 .3f0 .9  1 .9f0 .3  1 .5fO 
R + O  1.53 14.9 216 19 15.0 - - 2.0 1.8 
R +  1 - 14.2 368 - 14.7 - - - - 
R +  8 3.8 147 - 
R + 1 3  - 18.5 309 - 
R +  28 .49 11.0 280 18 - 39.2 6.9 1.8 1.2 
- - - - - - 
- - - - - 
a U  = standard unit. 
bDBH = diabetogenic hormone 
'IU = international unit. 
dT3 = triiodothyronine. 
eT4 = thyroxine. 
fTSH = thyroid stimulating hormone. 
gHGH = human growth hormone. 
hDashes indicate no data. 
'Preflight mean plus or minus standard deviation. 
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TABLE 14-III.-LACTIC DEHYDROGENASE ISOENZYME 
Band 1 Band 2 Band 3 Ea116 3 Rrrnd 5 
Sample day 
Percent IU Percent IU Percent IU Percent IU Percent IU 
F - 3 0  
F -  15 
F - 5  
R t  0 
R +  1 
R +  4 
R + 8  
R +  13 
R +  28 
F -  30 
F -  15 
F -  5 
R + O  
R +  1 
R + 3  
R + 4  
R + 8  
R t  13 
R t  28 
F -  30 
F -  15 
F -  5 
R+O 
R +  1 
R + 3  
R + 4  
R + 8  
Rt 13 
R +  28 
27 
28 
30 
23 
21 
22 
22 
24 
42 
31 
29 
26 
24 
29 
24 
25 
26 
26 
39 
33 
26 
28 
28 
24 
26 
26 
25 
27 
24 
44 
42 
48 
58 
- 
- 
42 
52 
97 
57 
47 
42 
64 
- 
- 
- 
60 
66 
95 
52 
38 
48 
57 
- 
- 
- 
50 
52 
47 
30 
28 
30 
26 
35 
31 
27 
26 
29 
33 
30 
26 
26 
27 
26 
27 
29 
28 
24 
35 
28 
25 
25 
26 
24 
25 
28 
31 
31 
ACDR 
49 15 
42 16 
48 15 
66 16 
- 16 
- 18 
51 18 
56 19 
67 21 
CMP 
61 12 
49 14 
42 15 
70 16 
- 17 
- 19 
- 18 
67 19 
71 19 
58 11 
DMP 
56 12 
41 15 
43 17 
51 15 
- 16 
- 19 
- 18 
55 18 
60 16 
61 15 
24 
24 
24 
41 
- 
- 
34 
41 
48 
22 
23 
24 
43 
- 
- 
- 
44 
48 
27 
19 
22 
29 
30 
- 
- 
- 
36 
31 
29 
9 
9 
6 
12 
8 
10 
13 
13 
4 
9 
9 
12 
11 
10 
10 
11 
10 
10 
8 
6 
10 
10 
11 
11 
12 
11 
10 
10 
10 
15 
14 
10 
30 
- 
- 
25 
28 
9 
17 
15 
20 
29 
- 
- 
- 
23 
25 
19 
10 
14 
17 
22 
- 
- 
- 
20 
19 
20 
19 
19 
19 
23 
16 
19 
20 
18 
4 
15 
18 
21 
23 
17 
21 
19 
16 
17 
18 
14 
21 
20 
21 
23 
19 
20 
19 
16 
20 
31 
39 
30 
58 
- 
- 
38 
39 
9 
28 
29 
34 
62 
- 
- 
- 
37 
43 
44 
22 
31 
34 
42 
- 
- 
- 
38 
31 
39 
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TABLE 14-IV.-URINE ENDOCRINE RESULTS 
Sample 24-h volume, Cortisol, bEpi, ‘Nor, d ~ ~ ~ ~ ,  e ~ ~ ~ ,  
day ml Clg/TVa PdTV PdTV Pg/TV mU/TV 
F-30  
F -  15 
F - 5  
PM f SD 
R +  0 
R +  28 
gF - 30 
gF- 5 
F -  15 
PM f SD 
R + O  
R +  28 
F -  30 
F -  15 
gF- 5 
PM f SD 
R +  0 
R +  28 
25 60 84.5 
1960 66.6 
2390 33.5 
2303 f 309 
2630 84.2 
750 24.0 
61.5 f 25.9 
1550 77.5 
1040 100.4 
1940 27.2 
1510+451 68.4+ 37.4 
1495 109.9 
1840 50.6 
2250 56.3 
750 105.0 
1350 19.6 
1450 f 755 60.3 * 42.8 
830 81.8 
1180 20.7 
ACDR 
5.2 
67.4 
L T D ~  
36.3 k 44.0 
2.8 
9.7 
CMP 
34.1 
21.1 
2.9 
19.4 k 15.7 
21.2 
6.0 
DMP 
LTD 
LTD 
LTD 
- 
7.8 
56.6 
66.1 11.2 
50.8 11.9 
104.6 23.6 
73.8 f 27.7 
74.1 32.8 
28.2 5.1 
15.6 f 7.0 
93.5 4.9 
74.2 8.8 
80.4 11.1 
82.7 f 9.9 
40.3 34.3 
69.1 6.3 
8.3 f 3.1 
108.9 11.4 
118.1 8.2 
65.7 7.1 
97.6 f 28.0 
61.3 32.8 
19.7 9.3 
8.9 f 2.2 
22.6 
178.2 
30.5 
77.1 f 87.6 
70.0 
11.5 
29.9 
93.8 
27.1 
50.3 + 37.7 
58.0 
8.4 
108.0 
72.0 
147.6 
109.2 k 37.8 
21.5 
77.4 
a~~ = totalvolume. 
bEpi = epinephrine. 
‘Nor = norepinephrine. 
dALDO= aldosterone. 
eADH = antidiuretic harmone. 
fLTD = less than detectable. 
%ample unsatisfactory. 
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TABLE 14-VI.-BODY COMPARTMENT RESULTS 
Total body 
exchangeable K 
Total body water Extracellular fluid Plasma 
Y 
Sample day 
Vol., Change, Vol., Change, Vol., Change, Qty., Change, 
ml percent liters percent liters percent meq percent 
F -  15 41 12 -1 52.8 -2 19.7 -3 4396 -5 
2753 +5 
R +  OASAP 3496 51.6 19.2 4181 
DMP 
F -  15 3972 -7 48.4 -2 19.8 -3 3372 -2 
R+OASAP 3708 47.3 19.2 2781 
TABLE 14-VII.-URLNAR Y, FREE, AND PEPTIDE-BOUND HYDROXYL YSINE 
[pmoles/g creatinine] 
ACDR CMP DMP 
day Total Free Peptide- Total Free Peptide- Total Free Peptide- 
bound bound bound 
~ ~ 
F -  30 59.88 6.97 21.91 110.71 12.79 51.94 53.20 7.08 14.30 
F -  15 65.98 18.31 10.66 69.82 18.39 22.13 43.46 9.52 2.10 
F -  5 79.38 9.71 36.56 90.68 9.55 40.09 76.81 19.28 20.97 
PM f SD 68.41 f 11.66 f 23.04 f 90.40 f 13.58 f 38.05 f 57.82f 11.98 f 12.46 f 
9.98 5.92 12.99 20.45 4.47 15.01 17.15 6.46 9.57 
R+O a97.48 13.89 44.39 a172.58 17.99 54.42 a100.62 a24.99 22.30 
R +  28 41.79 10.38 2.92 54.71 13.14 15.16 55.64 14.92 7.17 
ap <o.os. 
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TAB LE 1 4 V I I I  .- URINAR Y GL UCOS YL-GALACTOS YL HYDROXYL YSINE AND 
GALACTO.$YL HYDROXYL YSINE 
[pmoles/g creatinine] 
ACDR CMP DMP 
Sample day 
GLU-GAL GAL Ratio GLU-GAL GAL Ratio GLU-GAL GAL Ratio 
F -  30 17.72 13.28 1.33 30.03 15.95 1.88 18.46 13.36 1.38 
F -  15 22.34 14.67 1.52 19.58 9.72 2.01 21.76 10.08 2.16 
F - 5  22.41 10.70 2.09 25.84 15.20 1.70 23.09 13.47 1.70 
PM f SD 20.82 f 12.88 f 1.65 f 25.15 f 13.62 f 1.86 f 21.10 f 12.30f 1.75 f 
1.93 0.39 
R + O  18.57 a20.63 .90 a79.96 a23.21 3.32 a37.52 15.81 2.37 
R +  28 16.62 11.87 1.40 16.14 10.27 1.57 21.64 11.91 1.82 
2.69 2.01 0.40 5.26 3.40 0.16 2.39 
ap < O . O l .  
Because of the problems after entry, the complete postflight protocol was not followed; 
however, several findings do merit discussion in relation to the toxic fumes inhaled by the 
crewmen after flight. 
Because enzymes are responsible for biological regulation, the change of activity 
should appear early, and should precede many of the structural indications of tissue deg- 
radation after toxic inhalation and offer a sensitive method for detection before actual 
irreversible damage. In an assessment of the effects of the inhaled nitrogen tetroxide 
(N,O,) on the returning Apollo crewnien, the serum enzymes values are very useful. At 
sublethal concentration, oxidants such as those present in the rocket fuel may alter, im- 
pair, or  otherwise interfere with normal physiological systems. The physiological and 
pathological effects of the oxidant gases have been studied, whereas the biochemical ef- 
fects resulting from short-term and prolonged exposure to  these gases have not yet been 
completely defined. It has been proposed that the gas may act by way of enzyme systems 
or directly on the structural components of the lung (ref. 14-2). Previous studies of alter- 
ation in enzyme activity levels following exposure t o  irritants have revealed that changes 
occur early, even before clinical signs of the tissue damage. The results on the ASTP 
crewmen show elevations in several serum enzymes as soon as blood was drawn after 
recovery. 
Serum glutamic oxaloacetate transaminase is an enzyme that catalyzes the reversible 
transfer of the amino group from glutamic to  oxaloacetic acid. In man, it is found in 
cardiac, hepatic, skeletal muscle, renal, and cerebral tissue in decreasing concentrations 
(ref. 14-31. 
At recovery, increases in SCOT, SGPT, Alk Phos, and LDH were seen in most cases. 
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Glutamic pyruvic transaminase catalyzes the reversible transfer of an amino group from 
glutamic to pyruvic acid. It also has been found to  be widely distributed in humans. The 
high hepatic content compared t o  the relatively low concentration in myocardial and other 
tissues has led to  the application of SGPT determination to  the study of hepatic disease 
(ref. 144). 
Alkaline phosphatase, the first serum enzyme to be studied in hepatic disease, has 
been extensively applied to the differential diagnosis of liver involvement (ref. 14-5). Lactic 
dehydrogenase is the naturally occurring enzyme which readily catalyzes the reversible oxida- 
tion of lactic t o  pyruvic acid (ref. 14-6). The defined distribution in the five LDH isoenzymes 
suggests organ source of the particular isoenzyme fraction. The component isoenzymes of 
LDH were examined to  ascertain the effect of the N, 0, inhalation on the normal isoenzyme 
distribution. However, it must be made clear that the changes observed in the LDH isoenzyme 
patterns of the ASTP crewmen do not reflect damage in tissue other than lung. Buckley and 
Balchum (ref. 14-7) found that LDH enzyme activity was grossly elevated in lung, liver, and 
kidney tissue homogenates, whereas the isoenzyme pattern was significantly altered only in 
the lung tissue. Their findings suggest that nitrogen dioxide favors conditions which inhibit 
aerobic and stimulate anaerobic oxidation in lung tissue (ref. 14-7). 
In an attempt to  identify components of the inhaled gas which might have affected the 
crewmen, the postflight blood samples were analyzed for hydrazine (H) and l-methylhydra- 
zine (MMH). The results of the analyses were negative. The absence of these compounds 
was also confirmed by the lack of consistent change in serum cholesterol and triglycerides. 
The next section contains the findings from the H and MMH study. 
The 24-hour urine samples obtained after recovery were analyzed t o  evaluate the pos- 
sible effects of weightlessness on collagen degradation. The average values obtained from 
the preflight specimens for glucosyl-galactosyl hydroxylysine, for galactosyl hydroxylysine, 
and for the GLU-GAL/GAL ratio agree well with those given by Askenasi (ref. 1 4 8 )  and 
by Kakimoto and Akazawa (ref. 14-9) for normal subjects. The values for total hydroxylysine, 
free hydroxylysine, and peptide-bound hydroxylysine, however, are consistently higher in the 
ASTP series. 
and Hamilton (ref. 1 4 1  l) ,  and more recently of Askenasi (refs. 14-8 and 14-12) suggests that 
the urinary excretion of hydroxylysine metabolites may represent an index of collagen break- 
down. Little is known of the metabolic significance of the urinary free hydroxylysine apart 
from the fact that this is usually the least abundant metabolite and its excretion seems t o  
vary in different species (ref. 14-8). The excretion of the hydroxylysine glycosides is fairly 
constant in normal individuals, and it is considered to  be quite independent of dietary varia- 
tions (ref. 14-12). 
reported that the excretion of the disaccharides is more abundant in the course of skin dis- 
eases, whereas the excretion of the monosaccharides is more abundant in the course of bone 
diseases (refs. 14-8 and 14-1 2). The urinary peptide-bound hydroxylysine represents rel- 
atively large polypeptides with a composition similar t o  that of collagen. Because polypep- 
tides are considered to be related to collagen synthesis rather than t o  collagen degradation, 
their metabolic significance is not yet clear (ref. 14-13). 
The available information does not suggest that an increased urinary excretion of 
hydroxylysine metabolites might occur as a result of acute lesions of the pulmonary paren- 
chyma. However, such a possibility is not unlikely when one considers that 60 to 80 percent 
The work of Cunningham et al., (ref. 14-10), Kakimoto and Akazawa (ref. 14-9), Lou 
An increased excretion of glycosides has been demonstrated in various diseases; it is 
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of the dry weight of normal lungs is represented by collagen (refs. 14- 14 and 14- 1 3 ,  which 
must be spread on an extremely large surface. The knowledge that the three U.S. astronauts 
innaieci i v x k  fiiiiies after entry intc! the Earth’s atmosphere and subsequently developed symp- 
toms of chemical pneumonitis suggests that the increased urinary excretion of hydroxylysine 
metabolites might have been related t o  the acute destruction and/or increased permeability of 
lung parenchyma (ref. 1416). It is unfortunate that additional urine specimens were pro- 
hibited, because such specimens could have revealed even more meaningful changes, especially 
in relation to the clinical and radiological course of the lesions. However, the occurrence of 
situations in which toxic fumes may be inhaled accidentally should provide abundant material 
for the assessment of biochemical parameters of potential value for determining the prognosis 
of acute pulmonary lesions. 
. .  3 
ADDITIONAL DATA ON BLOOD HYDRAZINE AND 1-METHYLHYDRAZINE 
Blood drawn from the ASTP crewmen approximately 2 hours after recovery and in the 
morning of the day after recovery was analyzed for H and MMH according to  the procedure 
described by Reynolds and Thomas (ref. 1417). Table 14-IX contains the results of the 
study conducted m preparation for analysis of the crew samples. Blood was drawn from six 
normal controls and analyzed for H and MMH. Recovery studies were conducted by adding 
0.1 and 2.5 pg of H and MMH t o  each control sample. Comparisons were made between 
0.5 ml and 1 ml of serum samples and between plasma from blood treated with ethylene- 
diaminetetraacetate (EDTA) as an anticoagulant and serum. The results of the study on 
normal controls show that neither H nor MMH was detected. The recovery study demon- 
strated that both H and MMH were detectable in ranges of 0.1 and 2.5 pg. It was also shown 
that no significant difference was apparent between serum and EDTA plasma samples. Table 
1 4 X  contains the results on EDTA plasma for the three ASTP crewmen for recovery day 
and the morning of the day after recovery. The results show no detectable H or MMH at 
either time. 
the blood by the male Sprague-Dawley rats given large doses of intraperitoneal injections of 
H and MMH ranging from 0.5 to 60 mg/kg and 1.0 t o  15.0 mg/4 g, respectively. The absolute 
blood concentrations increased with increasing dosage and decreased with time after exposure. 
Blood levels were detectable when injected doses were 0.6 mg/kg and 3.0 mg/kg for H and 
MMH, respectively. 
Studies conducted by Reynolds and Thomas (ref. 14-1 7) showed a rapid clearance from 
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TABLE 14IX.-DETEMINATION OF HYDRAZINE AND 
I-METHYLHYDRAZINE IN BLOOD SERLW 
(a) Initial analyses 
Control subject Sample type Sample size, ml Qty found, pg 
H 
1 Serum and plasma 1 .o 
2 Serum and plasma 1 .o 
3 Serum and plasma 1 .o 
4 Serum and plasma 1 .O 
5 Serum and plasma 1 .o 
6 Serum and plasma 1 .o 
MMH 
1 Serum and plasma 1 .o 
2 Serum and plasma 1 .o 
3 Serum and plasma 1 .o 
4 Serum and plasma 1 .o 
5 Serum and plasma 1 .o 
6 Serum and plasma 1 .O 
0.0 
.O 
.o 
.o 
.o 
.o 
0.0 
.o 
.O 
.o 
.o 
.o 
(b) Recovery studies 
Control sample 
No. Type Size, ml 
Quantity added, pg Quantity recovered, pg 
1 
2 
3 
1 
2 
3 
1 
3 
5 
6 
Serum 
Serum 
Serum 
Plasma 
Plasma 
Plasma 
Serum 
Serum 
Serum 
Plasma 
1 .o 
1 .o 
1 .o 
1 .o 
1 .o 
1 .o 
.5 
.5 
.5 
1 .O 
~~~ 
H 
0.1 
.2 
.3 
. I  
.2 
.3 
.4 
.5 
1 .o 
2.5 
1.1 
.2 
.4 
.1 
.I25 
.25 
.4 
.5 
1 .o 
2.7 
4 
5 
6 
4 
5 
6 
2 
4 
6 
6 
Plasma 
Plasma 
Plasma 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
Serum 
MMH 
1 .o 
1 .o 
1 .o 
1 .o 
1 .o 
1 .o 
.5 
.5 
.5 
1 .o 
0.1 
.2 
.3 
.1 
.2 
.3 
.4 
.5 
1 .o 
2.5 
0.0 
.2 
.5 
.o 
.IS 
.3 
.5 
.6 
1.5 
3.2 
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TABLE 14-X.-RESULTS OF EDTA PLASMA ANALYSES 
EDTA sample 
(plasma), ml 
Subject Sample day 
AC DR 
CMP 
DMP 
R+O 
R + O  
R+O 
0.5 
.5 
.5 
0.0 
.O 
.o 
0.0 
.o 
.o 
ACDR 
CMP 
DMP 
Control 1 
Control 2 
Control 3 
Control 4 
Control 5 
Control 6 
aControI 3 
R +  0 
R +  1 
R t  1 
.5 
.5 
.5 
.5 
.5 
.5 
.5 
.5 
.5 
.5 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
2.7 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
.o 
3.2 
aControl 3, 2.5 ry H and MMH added. Recovery was the same as that for control 6. 
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15. HEMATOLOGICAL AND IMMUNOLOGICAL STUDIES 
Stephen L. Kimzep and Phillip C. Johnsonb 
The primary purpose of the hematological and immunological studies was to provide 
hematologic and immunologic data to the Apollo-Soyuz Test Project (ASTP) crew surgeon 
necessary for the objective assessment of the crew’s health status before launch and during 
the period immediately after flight. A secondary objective was to  evaluate the influence of 
space flight on the circulating blood volume. Supporting data and sample logistics were 
also provided for ASTP Experiment MA-031 , Cellular Immune Response (ref. 15-1), and 
Experiment MA-032, The Effects of Space Flight on Polymorphonuclear Leukocyte Re- 
sponse (ref. 15-2). 
BLOOD SAMPLE COLLECTION 
Blood samples were collected by venipuncture from the prime U.S. crewmen three 
times during the preflight period (approximately 30, 15, and 5 days before lift-off (days 
F - 30, F - 15, and F - 5, respectively) and during the 4 weeks following recovery (days 
R + 0 to  R + 29). In addition, identical samples were collected from the backup crewmen 
during the preflight phase and from three ground-based control subjects during the mission. 
Radioisotope studies (for the determination of red cell mass and plasma volume) were con- 
ducted on days F - 15, R + 0, and R + 29. The Apollo commander (ACDR) did not partic- 
ipate in these studies. The blood volumes and distributions are detailed in Table 15-1. 
, 
I 
I ROUTINE HEMATOLOGY 
The routine hematology data, including preflight mean (PM) and standard deviation 
I (SD), are summarized in Tables 1 S-II(a) and 1 S-II(b). Varying degrees of hemodilution 
were evident in all three crewmen after the flight (Figures 15-1 to 15-3). These changes in 
red blood cell (RBC) count, hemoglobin concentration (Hb), and hematocrit (HCT) are 
similar to those observed following previous manned space flights and reflect the changes 
in plasma volume and red cell mass. The decline in plasma volume and red cell mass of 
comparable magnitudes in the command module pilot (CMP) and the docking module pilot 
(DMP) are responsible for the lack of a significant change at R + 0 (except in the ACDR). 
The recovery of plasma volume at a rate faster than that for the red cell mass results in an 
apparent hemodilution during the first few days following recovery. 
I 
! 
I (These values are depicted in the subsection entitled “Radioactive Hematological Studies.”) 
I 
I 
I aNASA Lyndon B. Johnson Space Center. 
bBaylor College of Medicine, Houston, Texas. I 
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TABLE 1 S-I.-BLOOD SAMPLE SCHEDULE 
Sample day Sample volume, ml Comment 
- F - 30 90 
F -  15 90 Radioisotope studies 
F -  14 15 Type and cross-match 
F - 5  70 - 
R + O  
R +  1 
R +  1 
R +  2 
R + 4  
R + 8  
R +  13 
R + 29 
90 
45 
42 
32 
32 
40 
35 
35 
Radioisotope studies 
Drawn at Triplera 
Drawn at Tripler 
Drawn at Tripler 
Drawn at Tripler 
Drawn at Tripler 
Radioisotope studies 
- 
aTripler Army Medical Center, Honolulu, Hawaii. 
An elevation in methemoglobin occurred at R + 0 (mean = 4.2 percent) compared to 
preflight values (mean = 1.3 +- 0.4 percent). By day R + 1, the methemoglobin levels had 
dropped t o  a mean value of 2.0 percent. This transient rise in the methemoglobin levels was 
most likely caused by exposure of the crew to nitrogen tetroxide (N,Oq) vapors during entry. 
A significant elevation in the white blood cell (WBC) count after f ight was due t o  an 
increase in the absolute neutrophil number (Table 15-11(b), Figures 15-4 and 15-5). Although 
there was a decrease in the percentage of lymphocytes, the absolute lymphocyte count did 
not change after flight (Figure 15-6). A similar neutrophil elevation was observed following 
the Skylab flights but was typically back within preflight limits by day R + 1 .  In contrast, 
the elevated neutrophil levels persisted in the ASTP crewmen and even showed a further in- 
crease in two of the men. This continued elevation was possibly related to  the resultant 
pulmonary damage and subsequent steroid therapy during the postflight period. 
reticulocyte counts during the subsequent 2-week period, when the red cell mass was being 
replaced. However, based on previous data, only a modest response would be expected. 
Classification of reticulocytes, based on density of the residual intracellular ribosomal net- 
work, indicated no significant shift in the age distribution of the reticulocytes on day R + 0 
or day R t 1 (Table 15-111). 
The reticulocyte counts were unchanged immediately after flight. There are no data on 
IMMUNOLOGY STUDIES 
Total serum protein levels showed some postflight variation which was probably due to  
the changing plasma volume during this time. Serum protein electrophoretic patterns were 
normal, with the exception of a low value to albumin on day R + 28 in the DMP (Table 15-IV). 
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TABLE 1 S-II.-HEMATOLoG Y DATA ON ASTP CREWMEN 
(a) Red cell 
q%C, aRETIC, Hb, HCT, 'METHB, MCV, MCH, MCHC, Platelet count, 
3 
Sample 
day x10 /liter Percent g/dl percent percent flc Pg gldl mm 
F - 3 0  
F -  15 
F - 5  
PMd 
SDe 
R +  0 
R +  1 
R +  8 
R +  13 
R +  29 
r:- 30 
F -  15 
F - 5  
PM 
SD 
R + O  
R +  1 
R + 8  
R +  13 
R +  29 
F -  30 
F -  15 
F - 5  
PM 
SD 
R + O  
R +  1 
R + 2  
R +  8 
R +  13 
R +  29 
4.97 
4.97 
4.96 
4.97 
.01 
4.50 
4.77 
4.36 
4.45 
4.67 
4.72 
4.69 
5.07 
4.83 
.21 
4.88 
4.86 
4.42 
4.32 
4.81 
4.53 
4.32 
4.32 
4.39 
.12 
4.46 
4.84 
4.35 
4.19 
4.14 
4.22 
0.9 
1.0 
.6 
.83 
.21 
.7 
.5 
ND 
ND 
1.0 
1.2 
1.3 
.9 
1.13 
.2 
.8 
1.0 
ND 
ND 
.8 
0.9 
1.0 
.9 
-93 
.06 
.7 
N D  
.5 
ND 
ND 
1.1 
15.1 
15.5 
15.0 
15.2 
.26 
13.7 
14.2 
12.9 
13.3 
14 
14.7 
14.6 
15.7 
15.0 
.6 
15.3 
15 
13.3 
13.3 
14.5 
13.8 
13.1 
13.8 
13.6 
.4 
13.5 
14.4 
13.0 
12.6 
12.4 
13.2 
ACDR 
44 1.5 
44 1.2 
43 1.0 
43.7 1.23 
.6 .25 
39.5 2.8 
42 2.7 
37.8 ND 
38.7 ND 
43 1.1 
CMP 
42.5 2.1 
43.0 .8 
45.0 1.3 
43.5 1.4 
1.3 .7 
44.5 5.1 
44.0 2.1 
38.5 ND 
37.9 ND 
44 1.6 
DMP 
40.5 1.1 
39.0 1.5 
41.0 .9 
40.2 1.2 
1 .o .3 
40.0 4.6 
43.0 1.1 
39.0 ND 
36.4 ND 
35.9 ND 
37.0 .6 
89 
88 
89 
88.7 
.58 
88 
88 
87 
87 
92 
90 
92 
89 
90.3 
1.5 
91 
91 
87 
88 
91 
89 
90 
95 
91.3 
3.2 
90 
89 
89 
87 
87 
88 
30 
31 
30 
30.3 
.6 
30 
30 
29.7 
30 
30 
31 
31 
31 
31 
0 
31 
31 
30 
30.8 
30 
30 
30 
32 
30.7 
1.1 
30 
30 
29.9 
30.1 
30 
31 
34 
35 
35 
34.3 
.6 
35 
34 
34.2 
34.3 
33 
35 
34 
35 
34.6 
.5 
34 
34 
34.3 
34.9 
33 
34 
34 
34 
33.7 
34 
33 
33.4 
34.4 
34.5 
35 
.58 
337 000 
363 000 
308 000 
336 000 
27 500 
304 000 
294 000 
165 000 
252 000 
N D ~  
353 000 
371 000 
353 000 
352 333 
19 008 
364 000 
ND 
282 000 
269 000 
282 000 
267 000 
290 000 
263 000 
273 000 
14 572 
2 380 000 
ND 
ND 
192 000 
194 000 
242 000 
a~~~~~ = reticulocyte. 
bMETHB = methemoglobin. 
dPM = preflight mean. 
'SD = standard deviation. 
fND = not determined. 
= ferntoliter ( IO- '~/I) .  
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TABLE 15-II.-CONCLUDED 
(b) White cell 
Sample ~ W B $  h ~ ~ ~ ~ ,  NEUT, i ~ ~ ~ ~ ~ ,  LYMPH JMONO, k ~ ~ ~ ,  IBASO, BANDS, 
day mm percent mm 3 percent no., mm3 percent percent percent percent 
ACDR 
F -  30 
F -  15 
F -  5 
PM 
SD 
R + O  
R +  1 
R +  8 
R +  13 
R +  29 
F -  30 
F -  15 
F - 5  
PM 
SD 
R + O  
R +  1 
R +  8 
R +  13 
R +  29 
F -  30 
F -  15 
F- 5 
PM 
SD 
R + O  
R +  1 
R +  2 
R +  8 
R +  13 
R +  28 
6 700 
7 200 
6 400 
6 766 
404 
6 900 
11 700 
7 200 
6 400 
6 000 
5 400 
4 500 
6 200 
5 366 
850 
12 500 
10 900 
10 000 
7 800 
4 200 
4 700 
3 700 
5 200 
4 533 
764 
8 100 
11 000 
7 700 
8 300 
3 900 
3 700 
56 
60 
61 
59 
63 
77 
59 
61 
56 
2.7 
49 
43 
59 
50.3 
8.1 
88 
73 
44 
66 
58 
37 
32 
37 
35.3 
2.9 
73 
75 
56 
48 
43 
38 
3752 
4320 
3904 
2992 
294 
4347 
9009 
4258 
3904 
3360 
2 646 
1 935 
3 658 
2 746 
866 
11 000 
7 957 
4 400 
5 148 
2 436 
1739 
1184 
1424 
1449 
278 
5913 
8250 
4312 
3984 
1677 
1406 
42 2814 
37 2264 
31 1388 
28.7 2282 
2.9 779 
36 2484 
21 2457 
39 2808 
32 2048 
41 2460 
CMP 
45 2340 
54 2430 
34 1388 
44.3 2083 
10.0 602 
11 1375 
25 2725 
40 4000 
32 2496 
35 1470 
DMP 
61 2867 
64 2368 
57 2059 
60.7 2431 
3.5 408 
25 2025 
23 25 30 
35 2695 
42 3486 
47 1833 
54 1998 
2 
1 
1 
ND 
ND 
1 
2 
I 
5 
0 
0 
2 
6 
ND 
ND 
1 
2 
7 
0 
1 
0 
0 
2 
ND 
ND 
2 
1 
8 
3 
2 
2 
0 
2 
1 
ND 
ND 
0 
0 
4 
0 
3 
6 
1 
1 
ND 
ND 
0 
0 
9 
2 
6 
2 
4 
2 
ND 
ND 
0 
1 
1 
4 
8 
6 
0 
0 
0 
ND 
ND 
0 
0 
0 
0 
0 
0 
0 
0 
ND 
ND 
0 
0 
0 
0 
0 
0 
0 
0 
ND 
ND 
0 
0 
0 
1 
0 
0 
0 
0 
0 
ND 
ND 
0 
0 
1 
3 
0 
0 
0 
0 
ND 
ND 
0 
0 
0 
0 
0 
0 
0 
2 
ND 
ND 
0 
0 
0 
2 
0 
0 
gWBC = white blood cell. 
h~~~ = neutrophiL 
'LYMPH = lymphocyte. 
JMONO = monocyte. 
kEOS = eosinophil. 
'BAS0 = .  basophil. 
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Figure 15-6. Lymphocyte Count, 
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Although there was a 48-percent elevation in lactic dehydrogenase (LDH) levels on R + 0 
(R  + 0 mean = 241 mg percent; preflight mean = 162 mg percent), the distribution of the LDH 
isoenzymes did not change drastically, but there were slight elevations in the fifth band (Table 
15-V). The diagnostic significance of this small elevation in the fifth band is undetermined at 
this time. Lipoprotein fractions were normal (Table 15-V). 
The most significant alteration in serum protein quantitation (Table 15-VI) was a post- 
flight elevation in the haptoglobin concentration on all three crewmen (Figure 15-7). This 
change was observed frequently in crewmen returning from the Apollo space flights. It may 
reflect an acute phase protein response, perhaps caused by tissue destruction. Because of the 
toxic exposure of the ASTP crew during recovery and the subsequent lung tissue damage, it 
is impossible t o  identify the specific effects of space flight on the haptoglobin levels in the crew. 
The fact that the maximum values are observed 3 t o  4 days after recovery is also suggestive of 
a response to the toxic gas rather than t o  weightlessness. 
men (Table 15-VII), with the exception of a reduction in the IgG levels in the ACDR. The 
postflight (days R + 0 and R + 1) concentration of 909 mg/100 ml of serum is still within the 
normal range but is 34 percent below his preflight mean. 
change probably reflects the tissue destruction observed in the crew on day R + 1. 
No changes in immunoglobulins (IgG, IgA, IgM, IgD) were observed in any of the crew- 
The C-reactive protein was negative at R + 0 but strongly positive on day R + 1. This 
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TABLE 1 5-III.-RETICULoCYTE CLASSIFICATION 
Reticulocyte count, percent 
Class I Class I1 Class 111 
Crewman Sample day 
~ 
1.9 
2.0 
1.6 
41.6 
44.0 
46.2 
64.6 
54.0 
52.2 
ACDR F - 30 
F -  15 
F - 5  
CMP 
DMP 
F - 30 
F -  15 
F - 5  
1.8 
1.4 
3.6 
34.6 
38.8 
43.2 
63.6 
59.8 
53.2 
F - 20 
F -  15 
F - 5  
1 .o 
1.5 
4.8 
37.0 
29.3 
48.6 
62.0 
69.2 
46.6 
PM 
S D  
2.1 
1.2 
40.3 
6.0 
58.3 
7.2 
ACDR R + O  
R +  1 
3.4 
3.7 
33.6 
35.9 
63.0 
60.2 
63.3 
47.0 
CMP R t O  
R t  1 
2.8 
1.9 
33.8 
50.9 
DMP R + O  
R t  1 
1.5 
1 .o 
27.7 
28.8 
70.7 
70.2 
31.7 
3.4 
65.6 
4.3 
R t 0 mean 
SD 
2.5 
0.9 
2.2 
1.3 
38.5 
11.2 
59.1 
11.6 
R t 1 mean 
S D  
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TABLE 1 S-IV.-SERUV PROTEIN ELECTROPHORESIS 
[Grams per 100 ml] 
Globulins 
Sample day Total protein Albumin AI A2 B G 
HMa 
SD 
F -  30 
F -  15 
F -  5 
PM 
SD 
Rt 0 
Rt 1 
Rt4 
Rt 8 
Rt 13 
Rt 29 
HM 
SD 
F -  30 
F-  5 
PM 
SD 
Rt 0 
R +  1 
R+ 2 
R +  3 
Rt 8 
Rt 13 
R +  29 
F- I5 
HM 
SD 
F - 3 0  
F -  15 
F -  5 
PM 
SD 
R+ 0 
Rt 1 
Rt 3 
Rt4 
Rt8 
R+ 13 
R t 28 
1.3 
.4 
1.5 
1.4 
1.2 
1.4 
.2 
6.1 
6.1 
6.9 
1.1 
6.9 
1.3 
1.4 
.3 
1.2 
6.6 
6.8 
6.9 
.2 
1.2 
6.1 
6.5 
1.0 
6.5 
6.4 
1.1 
6.9 
.4 
6.8 
6.3 
6.6 
6.5 
.2 
1.0 
6.8 
6.8 
6.1 
6.8 
6.5 
6.4 
ACDR 
4.1 
.4 
4.4 
4.2 
4.2 
4.3 
.1 
4. I 
4.1 
3.8 
4. I
4.0 
5.0 
CMP 
4.6 
.4 
4.3 
3.8 
4.0 
4.0 
.3 
4. I 
3.8 
3.6 
4.0 
3.6 
3.5 
4.1 
DMP 
4.6 
.2 
4.3 
3.5 
4.1 
4.0 
.4 
4.3 
4.2 
3.1 
3.6 
3.9 
3.6 
b2.1 
0.2 
. I  
.3 
.3 
.2 
.3 
.os 
.3 
.2 
.3 
.3 
.3 
.2 
0.2 
. I  
.2 
.2 
.2 
.2 
.o 
.2 
.2 
.2 
.3 
.2 
.2 
.2 
0.2 
.O 
.2 
.3 
.2 
.2 
. I  
.2 
.2 
.4 
.4 
.2 
.3 
.4 
0.5 
.I 
.l 
.l 
.6 
.l 
.06 
.5 
.5 
.8 
.l 
.6 
.4 
0.6 
.2 
.6 
.6 
.6 
.6 
.O 
.l 
.l 
.l 
.l 
.l 
.l 
.5 
0.5 
. I  
.5 
.6 
.5 
.5 
.I 
.6 
.6 
.8 
.9 
.l 
.l 
.7 
0.8 
. I  
.9 
.9 
.8 
.9 
. I  
.l 
.8 
.8 
.8 
.8 
.8 
0.8 
.2 
.8 
.9 
.8 
.8 
. I  
.8 
.8 
.I 
.l 
.l 
.l 
.8 
0.8 
. I  
.9 
.8 
.8 
.8 
. I  
.9 
.8 
.6 
.6 
.9 
.8 
1 .o 
.2 
1.2 
1.3 
1.4 
1.3 
. I  
1.1 
1.1 
1.2 
1.2 
1.2 
.9 
I .3 
.I 
1.3 
1.1 
1.2 
1.2 
. I  
1.4 
1.3 
1.3 
1.3 
I .3 
I .3 
.9 
0.9 
. I  
.9 
1.1 
1.1 
1 .o 
. I  
1 .o 
1 .o 
1.3 
1.2 
1.1 
1.2 
1 .o 1.6 
~ ~ ~ ~~~~~~~~~~~~~~ ~ 
aHM = history mean (Defdtion - pooled value from previous mud physical examinations). 
boutside normal range. 
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TABLE 15-V.-LACTIC DEHYDROGENASE ISOENZ YMES AN..  LIPOPROTEINS 
[Percent] 
LDH bands Lipoproteins 
Sample day 1 2 3 4 5 A P R E B ~  B 
HM 
SD 
F -  30 
F -  15 
F -  5 
PM 
S D  
R + O  
R +  1 
R + 4  
R +  8 
R +  13 
R +  29 
HM 
SD 
F -  30 
F -  15 
F -  5 
PM 
SD 
R +  0 
R +  1 
R +  3 
R + 4  
R +  8 
R +  13 
R +  29 
HM 
SD 
F -  30 
F -  15 
F-5 
PM 
SD 
R +  0 
R-+ 1 
R +  2 
R + 4  
R + 8  
R +  13 
R + 2 8  
28 
5 
27 
28 
30 
28 
2 
23 
21 
22 
22 
24 
42 
33 
3 
31 
29 
26 
29 
3 
24 
29 
24 
25 
26 
26 
39 
24 
8 
33 
26 
28 
29 
4 
28 
24 
26 
26 
25 
27 
24 
28 
5 
30 
28 
30 
29 
1 
26 
35 
31 
27 
26 
29 
31 
5 
33 
30 
26 
30 
4 
26 
27 
26 
27 
29 
28 
24 
33 
6 
35 
28 
25 
29 
5 
25 
26 
24 
25 
28 
31 
31 
19 
3 
15 
16 
15 
15 
1 
16 
16 
18 
18 
19 
21 
17 
3 
12 
14 
15 
14 
2 
16 
17 
19 
18 
19 
19 
1 1  
17 
6 
12 
15 
17 
15 
3 
15 
16 
19 
18 
18 
16 
15 
ACDR 
9 
3 
9 
9 
6 
8 
2 
12 
8 
10 
13 
13 
4 
CMP 
8 
4 
9 
9 
12 
10 
2 
1 1  
10 
11 
10 
10 
8 
DMP 
1 1  
4 
6 
10 
10 
9 
2 
11 
11 
12 
11 
10 
10 
10 
10. 
16 
3 
19 
19 
19 
19 
0 
23 
16 
19 
20 
18 
4 
12 
4 
15 
18 
21 
18 
3 
23 
17 
21 
19 
16 
17 
18 
12 
5 
14 
21 
20 
18 
4 
21 
23 
19 
20 
19 
16 
20 
22 
7 
26 
29 
37 
31 
6 
31 
35 
21 
40 
35 
18 
27 
9 
25 
37 
30 
31 
6 
34 
26 
36 
31 
35 
35 
13 
45 
5 
36 
36 
31 
36 
1 
33 
30 
27 
35 
34 
34 
26 
20 
22 
23 
22 
22 
1 
17 
17 
22 
16 
20 
14 
.8 
19 
9 
20 
13 
21 
18 
4 
16 
20 
26 
25 
25 
25 
8 
3 
4 
12 
13 
20 
15 
5 
23 
24 
17 
19 
26 
22 
11 
57 
11 
52 
48 
41 
47 
6 
52 
48 
57 
44 
45 
68 
51 
9 
55 
56 
49 
53 
4 
so 
54 
38 
43 
40 
40 
19 
51 
8 
52 
51 
43 
49 
5 
44 
46 
56 
46 
40 
44 
63 
aPREB = prebeta. 
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TABLE IS-VL-SERUM PROTEINS 
[milligrams per IO0 ml] 
~ 
Sample day TRANSa W T O b  CERULO' A2MACROd A1 GLYCOe A1 ANTIf C3g 
HM 
SD 
F - 30 
F - 1 5  
F -  5 
PM 
SD 
R +  0 
R +  1 
R + 4  
R +  8 
R +  13 
R +  29 
HM 
SD 
F .30 
F -  15 
F -  5 
PM 
SD 
R+O 
R +  1 
R +  3 
R +  4 
R +  8 
R+ 15 
R t  29 
Hh4 
SD 
F -  30 
F -  15 
F - 5  
PM 
SD 
R t  0 
R +  1 
R +  3 
R + 4  
R + 8  
R +  13 
R +  28 
215 
17 
296 
258 
250 
268 
24 
258 
220 
296 
258 
288 
30 1 
I90 
22 
296 
312 
290 
299 
1 1  
190 
190 
25 1 
258 
210 
220 
204 
253 
47 
323 
258 
264 
28 1 
36 
243 
220 
28 1 
273 
197 
220 
334 
84 
1 5  
143 
152 
I55 
1 50 
6 
135 
131 
248 
212 
146 
98 
94 
30 
I53 
132 
144 
143 
10 
192 
216 
306 
322 
244 
199 
136 
184 
66 
135 
142 
148 
141 
7 
220 
261 
408 
399 
326 
322 
199 
33 
7 
33 
28 
32 
31 
2 
33 
29 
37 
38 
35 
30 
29 
4 
30 
29 
27 
28 
2 
32 
27 
40 
40 
28 
31 
24 
28 
5 
33 
27 
28 
29 
3 
27 
21 
39 
40 
33 
40 
27 
ACDR 
183 
57 
93 
115 
118 
109 
14 
106 
114 
100 
101 
101 
1 1 1  
CMP 
225 
40 
I34 
118 
121 
124 
9 
133 
116 
132 
127 
130 
139 
I94 
DMP 
141 
23 
97 
125 
121 
114 
1 5  
125 
128 
I07 
I07 
1 I3 
113 
146 
75 
16 
67 
64 
66 
66 
2 
48 
51 
85 
92 
1 1 1  
80 
61 
13 
48 
48 
52 
49 
3 
61 
56 
83 
83 
95 
92 
91 
58 
24 
48 
50 
66 
54 
10 
48 
42 
88 
85 
101 
96 
95 
294 98 
67 16 
187 109 
234 112 
236 98 
219 106 
28 8 
190 104 
177 118 
261 121 
177 117 
226 112 
161 112 
234 93 
54 32 
191 98 
234 98 
206 108 
156 101 
70 6 
166 112 
177 116 
227 114 
227 109 
185 108 
186 112 
165 116 
228 95 
42 38 
214 88 
193 91 
191 90 
199 90 
13 2 
198 108 
185 114 
251 108 
247 108 
239 98 
193 106 
199 117 
a~~~~ = tnnslminax. dA2 MACRO = A2 macroglobulin. 
bHAITO = haptoglobin e~~ CLYCO = AI glycoprotein. 
C~~~~~~ = ocrulopbsmin. f~~ ANTI = AI antitrypsin. 
k 3  = complement factor 3. 
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450 
400 
350 
- 
E m- 
F 
+ 5
g 200- 
250 i 
5 
0 -
m I
1% 
loo 
r 
- 
- 
- 
- 
- 
0 ACDR 
0 C M P  
50- 
F - 3 0  F - 2 0  F - 1 0  F - 0  R t O  R t l O  R t 2 0  R t 3 0  
Preflight Postf I ight 
Sample day 
Figure 15-7. Haptoglobin, ASTP U.S. Crewmen 
TAB LE 1 5 -V II .-IMMUNoGL OB UL INS 
[Milligrams per 100 ml] 
HM 
SD 
F-30 
F -  I S  
F- 5 
PM 
SD 
R+O 
Rt 1 
R+4 
R +  8 
R+ 13 
R+ 29 
1269 
222 
1419 
1419 
1309 
1382 
64 
909 
909 
1186 
93 1 
1086 
1064 
ACDR 
163 
28 
146 
156 
166 
156 
10 
159 
166 
182 
162 
174 
136 
87 
23 
97 
99 
101 
99 
2 
92 
90 
112 
113 
113 
68 
8 
3 
9 
8 
8 
8 
.5 
9 
8 
6 
6 
5 
9 
1 1 1  
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TABLE 15-VII.-CONCLUDED 
HM 
SD 
F - 30 
F -  15 
F - 5  
PM 
SD 
R + O  
R t  1 
R + 3  
R + 4  
R + 8  
R +  13 
R + 29 
HM 
SD 
F - 3 0  
F -  15 
F - 5  
PM 
SD 
R t O  
R t  1 
R + 3  
R + 4  
R + 8  
R +  13 
R +  28 
1297 
258 
1064 
1197 
998 
1086 
101 
1065 
1087 
1352 
1364 
1375 
1330 
1153 
947 
157 
798 
886 
887 
857 
51 
954 
932 
1230 
1230 
93 1 
998 
842 
CMP 
165 
20 
222 
166 
174 
187 
30 
156 
166 
185 
185 
157 
157 
156 
DMP 
229 
43 
205 
172 
189 
188 
17 
232 
236 
270 
265 
229 
232 
229 
161 
40 
121 
96 
121 
113 
14 
90 
104 
117 
121 
101 
106 
106 
137 
37 
97 
109 
116 
107 
10 
97 
99 
102 
97 
96 
96 
121 
5 
1 
6 
5 
5 
5 
.5 
5 
5 
4 
4 
5 
5 
4 
6 
3 
5 
5 
5 
5 
0 
6 
5 
5 
5 
6 
6 
N D ~  
aND = not determined. 
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SPECIAL HEMATOLOGY 
A significant shift occurred in the red cell shape classification after flight (Tables 15- 
VIII(a) and 1 5-VIIUb)). The percentage of discocytes (normal, biconcave red cells) dropped 
by 28 percent from a preflight mean of 79.8 to  an R + 0 mean of 57.4. There were signif- 
icantly more stomatocytes, spherocytes, and knizocytes after flight. There was also evidence 
of cell fragmentation and increased echinocytes (crenated cells). The percentage of discocytes 
in the postflight samples remained below the preflight mean throughout the postflight exam- 
ination period. The implications of these data are not clear at this time, but it would appear 
that the red cell shape classification was perturbed by the exposure to space flight and/or 
N, 0, (Figure 15-8). 
TABLE 1 S-VIII.-RED CELL SHAPE CLASSIFICATION 
[Percent] 
(a) Preflight and postflight to day R t 1 
Crewman Sample day Discocyte Stomatocyte Spherocyte Echinocyte Knizocyte Other 
ACDR F - 3 0  
F -  15 
F - 5  
CMP F - 3 0  
F -  15 
F -  5 
DMP F - 3 0  
F -  15 
F - 5  
PM 
SD 
ACDR R + O  
R +  1 
CMP R + O  
R t  1 
DMP R + O  
R +  1 
R t 0 mean 
R t 1 mean 
68.6 
76.8 
86.8 
77.4 
78.6 
83.2 
76.6 
85.4 
85.0 
79.8 
5.8 
51.2 
56.0 
61.2 
65.8 
59.8 
60.2 
57.4 
60.7 
Preflight 
2.2 9.0 
2.0 9.8 
1.2 5.0 
2.0 5 .O 
4.2 6.2 
1.8 6.4 
3.2 7.4 
2.6 7.0 
1.8 3.2 
2.3 6.6 
.9 2.1 
Post flight 
14.8 10.0 
11.4 19.0 
8.2 10.4 
2.8 5.4 
13.6 15.6 
4.8 4.2 
12.2 11.9 
6.3 9.5 
3.6 
2.4 
4.4 
2.8 
2.2 
4.2 
4.6 
.6 
3.8 
3.2 
1.3 
9.0 
2.0 
3.6 
10.8 
2.4 
7.4 
5.0 
6.7 
8.8 7.8 
5.2 3.8 
1.6 1 .o 
6.2 6.6 
5.2 3.6 
2.6 1.8 
3.8 4.4 
1.4 3.0 
1.2 5.0 
4.0 4.1 
2.6 2.2 
11.7 3.3 
10.8 0.8 
12.0 4.6 
7.4 4.2 
5.4 3.2 
9.8 13.6 
9.6 3.7 
9.3 6.2 
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TABLE 15-WII.-CONCLUDED 
(b) Postflight to day R+ 29 
Crewman Sample day Discocyte Stomatocyte Spherocyte Echinocyte Knizocyte Other 
ACDR R+O 51.2 14.8 10.0 9.0 
R+ 1 56.0 11.4 19.0 2.0 
R+2 65.4 2.6 13.2 5.6 
R+ 8 57.2 8.6 16.4 6.2 
R +  13 75.4 3.8 21.2 13.0 
R+ 29 75.4 1 .o 16.2 3.2 
CMP 
DMP 
R+ 0 61.2 8.2 10.4 
R+ 1 65.8 2.8 5.4 
R+ 2 67.4 8.6 9.0 
R +  8 71.6 4.6 12.0 
R+ 13 65.6 4.6 8.0 
4.8 R+ 29 62.4 1 .o 
R+O 59.8 13.6 
R+ 1 60.2 4.8 
R+ 2 70.4 3.0 
R+8 56.6 6.8 
R +  13 65.6 5.0 
R+ 29 61.6 .4 
5.6 
4.2 
1.6 
2.4 
1.6 
1.4 
Me an 62.6 5.9 12.3 
SD 6.3 4.2 4.4 
3.6 
0.8 
8.4 
7.4 
3.4 
4.8 
2.4 
7.4 
7.4 
4.6 
9.6 
9.2 
7.1 
3.4 
11.7 3.3 
10.8 0.8 
6.4 6.8 
3.4 8.2 
2.0 5.0 
1.8 2.4 
12.0 4.6 
7.4 4.2 
3.8 2.8 
1 .o 3.4 
3.6 4.8, 
10.0 7.0 
5.4 3.2 
9.8 13.6 
3 .O 4.6 
4.6 15.0 
3.0 5.2 
5.4 12.0 
5.8 5.9 
3.6 3.9 
90 0 Discocyte 
0 Stomatocytekpherocyte 
D Echinocyte 
75 
F - 3  F - 2 0  F - 1 0  F - 0  R + O  R t l O  R t Z O  R t M  
Preflight Postflight 
Sample day 
Figure 15-8. Red Cell Shape Classification, ASTP U.S. Crewmen 
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SUMMARY 
Most of the changes observed in the hematologic and immunologic functions of the 
ASTP crewmen as a result of their exposure to  space flight were subtle and/or transient. 
The changes in RBC, Hb, and HCT were the result of shifts in plasma volume during the 
flight and immediately after flight. The exposure of the crew t o  a toxic gas during entry 
complicates the interpretation of those changes observed. This exposure may have particular 
significance with respect to  the altered red cell shape profile after flight and its slow rate of 
recovery. 
RADIOACTIVE HEMATOLOGICAL STUDIES 
Red cell mass decreases were found in the two crewmembers tested at recovery. The 
mean decrease of 8 percent was less than the -1  0.1 * 1.3-percent mean of the crewmen who 
took part in the Apollo lunar landing missions. The change noted in the CMP was two and 
one-half times that of the DMP. On day R + 28, the loss in red cell mass of the CMP had 
been made up with both crewmembers showing a 3-percent decrease over the premission 
value. A decreased chromium-5 1 ( 5  Cr) red cell survival was found in the DMP’s results but 
not in the CMP’s results. The 1 I-percent mean decrease in plasma volume was larger than 
the 4.4 ? 1.7-percent mean decrease of the Apollo 14 to  17 crewmen. It is possible that the 
exposure to the chemical irritant may partly account for the greater decrease in plasma 
volume after this mission than after Apollo missions. The plasma volume of both crew- 
members had essentially returned to  the preflight value by day R + 28. The increased 
plasma volume loss of these two crewmembers produced higher peripheral HCT’s obtained 
as soon as possible (ASAP) after recovery (41) than were obtained before flight (44). This 
deviation is different from Apollo missions, for which mean HCT did not change (0.1 k 0.9 
percent) between preflight and ASAP values. The decreased plasma volume caused an in- 
crease in the total body hematocrit for one crewmember and no change for the other crew- 
member. A 3.0 f 1.3-percent decrease in total body hematocrit was seen in Apollo ASAP 
measurements. Total body HCT values did vary on the three occasions it was measured. 
of crew medical problems, the 2-hour samples were not drawn; therefore, the value cannot 
be calculated. 
During ASTP, measurements of spleen-liver ratios were performed. The ratio did not 
rise in the crewmembers, but it did in the controls. This result is evidence against splenic 
trapping having been the cause of the decreased red cell mass of the crewmembers. The 
radioactive hematological data are summarized in Tables 15-IX(a) and 15-IX(b). 
Radioactive iron was injected for determination of iron turnover at recovery. Because 
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TABLE 15-1X.-RADIOACTIVE HEMATOLOGICAL RESULTS 
(a) Baseline data 
Crewman Control subject 
Sample day 
DMP CMP 1 2 3 
F -  15 
ASAP 
R +  28 
F -  15 
ASAP 
R +  28 
F -  15 
ASAP 
F -  15 
ASAP 
F -  15 
ASAP 
R +  28 
F -  15 
ASAP 
R t  28 
F -  15 
ASAP 
R +  28 
Total red cell mass, ml 
2109 2560 1990 2158 
2017 2300 2036 2143 
2037 2480 - - 
Total plasma volume, ml 
3972 4112 3442 3294 
3708 3496 3467 3541 
3948 3874 - - 
Red cell mass, ml/kg 
27.8 31.7 29.2 29.1 
27.7 29.6 29.7 28.8 
Plasma volume, ml/kg 
52.3 50.9 50.5 44.5 
50.9 45.0 50.5 47.6 
39 43 
41 46 
39 44 
Peripheral hematocrit 
41 
41 
44 
43 
Total body hematocrita 
35 38 31 40 
35 40 37 38 
34 39 - - 
Total body hematocrit to peripheral hematocrit ratio 
0.90 0.88 0.90 0.91 
.85 .87 .90 .88 
.87 .89 - - 
2320 
2358 
3364 
3659 
32.7 
33.0 
47.4 
51.2 
44 
44 
41 
39 
9.93 
.89 
aCalculated from RBC mass and plasma volume determinations. 
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TABLE 15-1X.-CONCLUDED 
(a) Baseline data (continued) 
Crewman Control subject 
Sample day 
DMP CMP 1 2 3 
51Cr red cell survival, days 
28 24 29 
21 23 28 
Preflight 
In-flight 
25 
24 
24 
26 
Spleen to liver ratio 
0.89 0.93 1.03 
.86 .9 1 1.68 
Preflight 
Postflight 
1.35 
1.99 
(b) Percent of preflight value 
Crewman 
DMP CMP 1 
Control subject 
2 
Sample day 
3 
Total red cell mass 
ASAP 
R +  28 
96 90 102 
97 97 - 
99 
- 
102 
- 
Red cell mass, ml/kg 
100 93 102 ASAP 99 101 
Total plasma volume 
93 85 101 
99 97 - 
ASAP 
R+ 28 
107 
- 
109 
- 
Plasma volume, ml/kg 
97 88 100 ASAP 107 108 
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16. CREW HEIGHT MEASUREMENT 
Jeri W. Browna 
Gross effects of zero g on man’s anthropometry were observed during and after extended 
orbital flight periods of the Skylab Program. In the weightless state, the crewmen “grew 
taller” and the one-g erect body posture was altered at several skeletal joints, namely, the 
neck, shoulder, elbow, hip, knee, and ankle. 
tween the crewman and his work station equipment and flight clothing, particularly the space 
suit. The Apollo-Soyuz Test Project (ASTP) mission provided this opportunity to quantify 
the effects of zero g on crewman height and to  determine the change a? a function of time 
over a mission length comparable t o  the projected initial Space Shuttle fiights. 
Quantification of these effects is important for optimizing the physical interfaces be- 
MEASUREMENT DATA 
Approved data requirements for human engineering preflight, in-flight, and postflight 
measurements consisted of maximum stature, sitting height, and eye-level height. The pre- 
flight data on the ASTP crewmen were obtained during the routine physical examinations 
conducted 45, 30, and 15 days before lift-off (F - 45, F - 30, and F - 15, respectively). In- 
flight data measurements were completed during three mission phases: 
1. After launch, in the command module (CM) before docking module (DM) transfer - 
Sitting height and eye-level height were measured as soon as possible after weightlessness was 
attained . 
2. After DM entry and before DM jettison - Stature and eye-level height were meas- 
ured periodically in the DM. 
3. After DM jettison and before entry - Sitting height and eye-level height were 
measured in the CM as late as possible before entry. 
Because of scheduling problems and the limited number of data points completed, only 
the stature measurements from the second phase will be discussed in this report. Because of 
crew health concerns, a minimal number of postflight measurements were made. 
RESULTS AND DISCUSSION 
The anticipated increase in stature was noted in each of the ASTP crewmen (Table 16-1). 
This increase can probably be attributed to  the absence of g-loading on the spine which re- 
sulted in loss of normal spinal curvature and in expansion of the intervertebral disks. 
aNASA Lyndon B. Johnson Space Center. 
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TABLE 16-L-CREW HEIGHTMEASUREMENTS 
Preflight In-flight Postflight 
Crewman Measurement, Measurement, Measurement, 
Day cm (in) Day cm (in) Day cm (in) 
Apollo commander F - 4 5  181.3 (71.4) 6 180.6 (71.1) R + O  182.6 (71.9) 
F - 3 0  181.5 (71.5) 8 185.4 (73.0) 
F -  15 181.1 (71.3) 9 188.0 (74.0) 
Dockingmodule pilot F - 4 5  178.8 (70.4) 6 181.1 (71.3) R + O  180.5 (71.1) 
F - 30 179.1 (70.5) 8 182.9 (72.0) 
F - 15 179.0 (70.5) 9 180.1 (70.9) 
Commandmodule pilot F - 4 5  179.4 (70.6) 6 181.9 (71.6) R + O  180.5 (71.1) 
F - 3 0  180.2 (71.0) 8 181.9 (71.6) 
F -  15 180.4 (71.0) 9 186.4 (73.4) 
These data, in conjunction with Skylab height data, indicate a two-step “growth.” Only 
a small change (less than 1.3 cm (0.5 in.) average) occurred between launch and mission day 6, 
which was the first measurement opportunity in the DM. The major change, as much as 6.6 cm 
(2.6 in.) total, occurred between mission days 6 and 9. 
sidered, the following seems most probable. The smaller initial change may result from remov- 
ing g-loads on the body and thus permitting loss of spinal curvature. A similar expansion is 
observed on Earth when stature is compared between standing and supine body positions. The 
second larger “growth” may be accounted for from the expansion of the now unloaded inter- 
vertebral disks; this expansion may be further affected by the body fluid shifts in zero g (ref. 
1 6  1). Application of these data is being made in future man-machine interface designs. 
Although various hypotheses accounting for this time/stature relationship are being con- 
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